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Arbete och Hälsa (Work and Health) is a
scientific report series published by the
National Institute for Working Life. The
series presents research by the Institute’s
own researchers as well as by others, both
within and outside of Sweden.  The series
publishes scientific original works, disser-
tations, criteria documents and literature
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group and welcomes articles in different
areas. The language is most often English,
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welcome.
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Preface
The Criteria Group of the Swedish National Institute for Working Life (NIWL) has the
task of gathering and evaluating data which can be used as a scientific basis for the
proposal of occupational exposure limits given by the Swedish Work Environment
Authority (SWEA). In most cases a scientific basis is written on request from the SWEA.
The Criteria Group shall not propose a numerical occupational exposure limit value but,
as far as possible, give a dose-response/dose-effect relationship and the critical effect of
occupational exposure.
In searching of the literature several databases are used, such as RTECS, Toxline,
Medline, Cancerlit, Nioshtic and Riskline. Also information in existing criteria documents
is used, e.g. documents from WHO, EU, US NIOSH, the Dutch Expert Committee for
Occupational Standards (DECOS) and the Nordic Expert Group. In some cases criteria
documents are produced within the Criteria Group, often in collaboration with DECOS or
US NIOSH.
Evaluations are made of all relevant published original papers found in the searches. In
some cases information from handbooks and reports from e.g. US NIOSH and US EPA
is used. A draft consensus report is written by the secretariat or by a scientist appointed
by the secretariat. The author of the draft is indicated under Contents. A qualified
evaluation is made of the information in the references. In some cases the information can
be omitted if some criteria are not fulfilled. In some cases such information is included in
the report but with a comment why the data are not included in the evaluation. After
discussion in the Criteria Group the drafts are approved and accepted as a consensus
report from the group. They are sent to the SWEA.
This is the 23rd volume that is published and it contains consensus reports approved
by the Criteria Group during the period July 2001 to June 2002. These and previously
published consensus reports are listed in the Appendix (p 57).
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1Consensus Report for
4,4´-Methylenedianiline (MDA)
October 3, 2001
This work is an update of the Consensus Report published in 1987 (36).
Chemical and physical data. Uses
CAS No.: 101-77-9
Synonyms: 4,4´-diaminodiphenylmethane
bis-(4-aminophenyl)-methane
4,4´-methylenebisaniline
4-(4-aminobenzyl)-aniline
Formula: C13H14N2
Structure:
Molecular weight: 198.27
Boiling point: 398 – 399 °C
Melting point: 91.5 – 92 °C
Vapor pressure: 1.2 kPa (9 mm Hg) at 232 °C;
calculated 1.33 x 10-7 kPa (1 x 10-6 mm Hg)
at 20 °C (16)
Solubility: 0.1 g/100 g water
Distribution coefficient: log Poctanol/water = 1.6 (22)
Pure 4,4´-methylenedianiline at room temperature is a crystalline powder with a
weak amine odor. It dissolves easily in alcohol, benzene and ether, but only
slightly in water (1). Industrial grade MDA is a liquid, and typically has the
following composition:
4,4´-MDA 60%
MDA polymers 36%
2,4´-MDA 3.5%
2,2´-MDA < 0.1%
water < 300 ppm
aniline < 100 ppm.
MDA is used in the production of various polymers and plastics. Most of it is
used in closed systems to make methylenediphenyl diisocyanate (MDI) and
CH2NH2 NH2
2polyisocyanates for use in production of polyurethane. MDA is also added to
rubber as an antioxidant and to epoxy products and neoprene as a hardener.
Smaller amounts are/were used in rust preventives and azo dyes for leather and
hair (36).
Occupational exposure occurs mostly during production of MDA or polymers.
However, emissions of MDA and MDI have also been detected around use of
finished products – heating polyurethane foam, for example (12, 25, 38). MDA
and its metabolites have been found in hydrolyzed urine and plasma from workers
exposed to MDI, and exposure to MDI thus implies potential exposure to MDA
(50). To measure individual exposure to airborne MDA, samples are taken on
acid-treated fiberglass filters and analyzed by liquid chromatography (16).
Uptake, biotransformation, excretion
Uptake
At room temperature MDA occurs almost entirely in aerosol form, and it can be
taken up via respiratory passages, skin and digestive tract. In occupational
exposures, most MDA enters the body via skin and respiratory passages (9).
Several reports describe skin uptake as the primary path of exposure (7, 8, 37).
One study reviews several cases of MDA-induced hepatitis in a plastics factory
during the years 1966 – 1972. The problems caused by the poor work environ-
ment were addressed, and in 1971 the workers had begun using helmets with
separate air intakes and the reported MDA concentrations in the air were low: in
the range 1.6 to 4.4 µg/m3 outside the helmet and 0.6 µg/m3 inside the helmet.
Despite these improvements, there were more cases of liver damage during 1971 –
72. All the workers who developed hepatitis had been kneading a paste of MDA
plastic protected only by cotton gloves, and had worked with their hands in the
plastic for several hours per day. Workers with other tasks at the workplace were
unaffected (37).
Skin uptake was quantified by Brunmark et al.: five volunteers were given
patch tests with 0.75 – 2.25 µmol MDA in isopropanol. An average uptake of
28% was calculated from analysis of the MDA remaining in the patch test
chamber after 1 hour of exposure (6). Calculations based on this result yield an
uptake rate of 0.24 µg/cm2/hour.
Biotransformation
Biotransformation has been found to be an important factor in acute toxicity,
genotoxicity and elimination of MDA (2, 6, 27, 31). Several metabolites and a
few MDA-metabolizing enzymes have been identified, but mapping of MDA
metabolism is far from complete.
N-Acetyl MDA has been identified as the primary metabolite in the urine of
exposed workers (8). MDA and acetyl-MDA have also been found as hemoglobin
adducts (47). Valine adducts in hemoglobin were isolated in order to identify the
genotoxic reactive intermediates of MDA. A valine adduct of hemoglobin was
3identified, and it was proposed that the reactive intermediate is 1-[(4-imino-2,5-
cyclohexadiene-1-ylidene)-methyl]-4-aminobenzene (31). The cytochrome P450
system has been found to be involved, and several reactive intermediates have
been identified (2, 27) (see Figure 1). MDA treatment of rats increases enzyme
activity in their livers (57).
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Figure 1. Proposed metabolism of MDA. References are given within parentheses.   
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4It is important to bear in mind that MDI may be hydrolyzed to MDA in vivo.
Rats were exposed to an aerosol of MDI for 3 to 12 months, and although no
MDA was detected in the exposure chamber both MDA and acetyl-MDA were
identified in the rats’ urine and the corresponding hemoglobin adducts in their
blood (50). MDA and acetyl-MDA have also been detected in urine and as
hemoglobin adducts in blood from workers exposed only to MDI (47). The
analysis method, however, involves hydrolysis of the plasma or urine, which
means that MDI can be transformed to MDA during the sample processing.
Figure 1 summarizes the proposed metabolic pathways for MDA.
In a study of elimination and absorption kinetics, 5 volunteers were given 1
hour of epicutaneous exposure to 0.75 – 2.25 µmol MDA. It was found that the
plasma concentration was highest 3 to 7 hours later, and the calculated half time
for the elimination phase was 9 to 19 hours. The highest levels in urine were noted
6 to 11 hours after the exposure, and the half time in urine was 4 to 11 hours (6).
A similar study of workers exposed to heated polyurethane foam showed con-
siderably longer elimination times: the half times were determined to be 10 to 22
days in plasma and 59 to 73 hours in urine (13). The observation that in these two
studies the half time for elimination was shorter in urine than in plasma can be
explained by assuming that MDA probably exists in at least two compartments
with different half times (free and protein-bound MDA, for example), or that the
observation time was too brief.
Excretion
MDA is excreted in both urine and feces (16). The distribution between excretion
pathways varies with species and method of administration (16).
There are no complete data from human exposures. However, Brunmark et al.
report that only 16% of absorbed MDA was excreted in urine within 50 hours of
exposure and that MDA in urine was subsequently below the detection limit. They
conclude that MDA is probably excreted and metabolized in other ways as well,
and may be stored in the body (6).
Biological measures of exposure
Since skin uptake accounts for a large portion of total uptake, methods have been
developed for biological exposure monitoring. These are gas-chromatographic-
mass spectrophotometric analysis of MDA and acetyl-MDA in urine (7), in
plasma (13), and as hemoglobin adducts in blood (50). Analysis of MDA con-
centrations in urine is suitable for estimating exposures during a workshift, but
several measurements both post-shift and pre-shift are required if the results are to
be reliable (6, 12). For estimating exposures over longer periods, there is a method
based on quantitative analysis of MDA and acetyl-MDA in hemoglobin adducts
(47, 50). Workers exposed to low levels of MDA or MDI were examined, and
acetyl-MDA and MDA were found (after hydrolysis) in the urine and blood of
most of them, although in most cases the air concentration was below the de-
tection limit. Biological exposure monitoring is proposed as a sensitive method of
assessing exposure to MDA and MDI (47, 50). In order to identify high exposure
5during a single workshift, and for quantitative estimates of longer exposures,
measurements of MDA in both blood and urine are recommended (47). However,
this method can not differentiate between MDA exposure and MDI exposure.
Toxic effects
Human data
Several incidents of MDA poisoning have been reported, after oral intake of
contaminated bread or drink as well as after occupational exposure via skin or
inhalation. In all cases the amount of MDA taken up is unknown. Regardless of
whether the uptake was dermal, oral or via inhalation, the result was liver damage
(3, 5, 32, 33, 37, 44, 53). A retrospective study reviews 12 cases of chemical
hepatitis that occurred in the 1966-1972 period at a plastics factory where these
workers made insulation containing MDA. They kneaded a plastic paste with their
hands, and became ill after one to three weeks of work at the factory but one or
two days after beginning work with the plastic. All 12 had jaundice and dark
urine, and 5 also had skin rashes. In the report it is pointed out that other workers
doing the same task did not become ill, and that differences in exposure or in
sensitivity to MDA were possible reasons for the difference in risk (37).
Another case report describes floorlayers who developed jaundice and stomach
cramps. They used MDA as hardener in an epoxy glue that they mixed on site (3).
A third study describes an occupational exposure in a chemical plant where large
quantities of MDA were used. A young man was exposed to MDA when the air
filtration system broke down, spraying MDA into the air as a yellow dust. While
the system was being repaired he took a lunch break and removed the top part of
his protective overalls, leaving his upper body covered only by a T-shirt. In
addition to stomach pains he developed a skin rash and hepatitis, as well as acute
myocardiopathy (5). Yet another study describes a man who drank an unknown
amount of MDA dissolved in potassium carbonate and butyrolactone. His vision
was affected, and he developed jaundice and temporary heart problems. Eighteen
months later his vision had still not recovered (44).
The most remarkable poisoning incident occurred in Epping, U.K, in 1965,
when 84 persons developed jaundice and other symptoms after eating bread
contaminated with MDA (32). The jaundice lasted for 1.5 to 4 months, and the
patients felt unwell for several weeks after the symptoms of jaundice had
disappeared. Liver biopsies revealed portal inflammation, eosinophil infiltration,
bile duct inflammation, bile stasis and various degrees of cell damage (33). All the
victims recovered without further complications within a year (33). A bit of the
contaminated bread was analyzed, and the total dose was estimated to have been
about 3 mg/kg body weight. It is emphasized, however, that this figure is highly
speculative: only one slice of bread was analyzed, it is known that the MDA was
unevenly distributed in the contaminated flour, the analysis method is presumably
inaccurate, and the total bread intake of each individual is unknown (20, 32).
6Skin
Direct contact with MDA colors the skin, nails and hair yellow (10), and several
studies have demonstrated that MDA is a contact allergen. Several case reports
describe positive reactions to patch tests with MDA, but it is uncertain whether
MDA induced the hypersensitivity or the positive reactions are due to a cross-
reaction with similar para-amino compounds (4, 16, 18, 28, 45). Studies by Von
Gailhofer and Kanerva, however, indicate that MDA causes skin sensitization.
Von Gailhofer and Ludvan (18) found that 39 of 202 patients had positive
reactions to MDA only, and their data indicate that workers in chemical
laboratories have an elevated risk of developing contact allergy to MDA. Kanerva
et al. (28) found that MDA was the second most common contact allergen on
patch tests given to patients with suspected occupational dermatosis after contact
with plastic chemicals. They tested 174 patients with their ‘plastic and glue series
no. 1,’ and 2.9% were positive to MDA. In a previous study the same group had
examined 6 patients occupationally exposed to isocyanates: 5 of them had
reactions to both MDA and MDI, 3 to an additional 5 isocyanates, and 1 to MDA
alone. Primary sensitization to MDA and a cross-reaction to MDI is the most
likely explanation, but primary sensitization to MDI is also a possibility (15). One
case of photosensitization has been reported (34).
Animal data
MDA is acutely toxic to several animal species, including rats, mice, guinea pigs,
rabbits and dogs, when given in oral doses of 100 to 800 mg/kg (23). Cats have
been found to be more sensitive, with liver and kidney damage after a single dose
of 10 mg/kg (16). Acute toxic effects in all species are liver and kidney damage,
and cats also go blind. The LD50 for oral administration to Wistar rats was 830 mg
MDA/kg body weight (43). Rats exposed to MDA for several weeks developed
liver cirrhosis (39, 58) or liver fibrosis and inflammation in the portal area (46). In
rats given 1000 ppm MDA in diet for 8 to 40 weeks, there was intraheptic bile
duct proliferation in addition to a duration-dependent increase in the previously
mentioned types of liver damage (17).
Hypertrophy of adrenals, uterus and thyroid was observed in ovarectomized
rats given MDA by gavage in doses of 150 mg/kg/day for two weeks (54). Other
effects seen in rats given similar subchronic doses are degeneration of liver,
kidneys and spleen (17, 19, 24). In a 13-week study by the National Toxicology
Program (NTP), rats and mice were given MDA dihydrochloride (MDA-2HCl)
in drinking water, 0 to 800 mg/liter. There were dose-dependent increases in the
frequencies of hyperplasias in bile ducts and thyroids, and at the highest dose
goiter as well. The highest dose having no observed effect was 100 mg/liter (≈ 6 -
7 mg/kg for rats, 13 - 16 mg/kg for mice) (40). For rats, the toxicity threshold
for a single exposure is estimated to be between 25 and 75 mg/kg (2). Recent
morphological studies have shown that bile duct epithelial cells are damaged first.
Necrosis in intrahepatic bile ducts had become severe within 6 hours after oral
administration of MDA (50 mg/kg), and less severe damage was seen in small
7peripheral bile ducts (30). Kanz et al. found toxic compounds in the bile of rats
4 hours after a single oral dose of 250 mg/kg (29).
Effects on drug-metabolizing enzymes in rat liver were studied, and the lowest
single dose that yielded a significant effect was 50 mg/kg (57). Dose-effect
relationships observed in studies with rats and mice are summarized in Table 1.
Mutagenicity
Several experiments, both in vivo and in vitro, have shown that MDA is
mutagenic and genotoxic. MDA was found to be mutagenic in Salmonella
typhimurium strains TA98 and TA100 only after activation with S9. The N-
acetylated metabolites were not mutagenic under the same conditions (41, 52).
MDA induced DNA repair in rat hepatocytes (38). Exposure to MDA in vivo
induced sister chromatid exchanges in bone marrow cells and DNA strand breaks
in hepatic cells (41, 42). MDA-induced DNA adducts have been detected with the
32P-postlabeling method and by injection of radioactive MDA (48, 55). MDA is
clearly mutagenic in vitro and genotoxic in vivo.
Carcinogenicity
The International Agency for Research on Cancer (IARC) has classified MDA
as “possibly carcinogenic to humans” (Group 2B) (25, 26). The European
Commission has placed MDA in Category 2, with the risk description “may
cause cancer” (R45) (14). The results of cancer studies with rats and mice are
summarized in Table 2 and below.
Animal data
The NTP conducted a well controlled cancer study in which Fischer-344 rats and
B6C3F mice of both sexes, 50 animals per group, were given MDA in drinking
water (two different dose levels) for two years. The study showed that MDA
caused tumors in liver and thyroid (56). The rats received water containing 0, 150
or 300 mg MDA hydrochloride/liter, corresponding to a daily MDA intake of 0, 9-
10 or 16-19 mg/kg. There was no effect on survival. At the highest dose level, the
incidences of thyroid carcinomas in male rats and of thyroid adenomas in female
rats were significantly higher than in controls. A dose-related increase of hepato-
cellular neoplastic noduli was also observed in the male rats (56). The same test
protocol was followed with the mice. They were given drinking water containing
0, 150 or 300 mg MDA hydrochloride/liter, corresponding to a daily MDA intake
of 0, 19-25, or 43-57 mg/kg. For males, survival was significantly lower in the
high-dose group than in the low-dose or control groups. As with the rats, the
greatest effects were on liver and thyroid. The incidences of hyperplasia and
adenoma in thyroid were significantly higher in both males and females receiving
the high dose. A dose-dependent increase in hepatocellular carcinomas was
observed in both sexes, and of hepatocellular adenomas in females (56). Smaller
8or poorly documented studies also indicate that MDA has a carcinogenic effect
(39, 46, 51).
Using the results of the animal experiments made by the NTP, the Dutch Expert
Committee on Occupational Standards (DECOS) made a linear extrapolation
yielding a calculated increase of cancer risk for MDA exposure: 4 x 10-5 with 40
years of exposure to 0.009 mg MDA/m3 (21).
Human data
Seldén et al. studied 550 Swedish power plant workers probably exposed to MDA
and found one case of bladder cancer (expected 0.6) (49). Cragle et al. compared
263 chemical process workers with 271 unexposed workers from the same factory
and found five cases of bladder cancer among the exposed workers (expected
0.66), a significant increase (11). None of the five had worked with MDA,
although there was indirect exposure. All five, however, had been exposed to
trichloroethylene (11).
Liss and Guirguis report one case of bladder cancer among 10 former workers
in a factory that made epoxy paste, all of whom had been poisoned by MDA at
some time during the 1967-1976 period (35).
In a follow-up 24 years after the accident in Epping, where exposure consisted
of high doses of MDA in contaminated bread consumed during a fairly short
period, no chronic effect of the poisoning could be seen in the 68 victims (81%)
that could be traced. This study unfortunately has little value, since the docu-
mentation is poor and the investigation was incomplete (20).
In summary, studies of occupational exposure are limited by the small number
of cases and the prevalence of mixed exposures. Several aromatic amines similar
to MDA can cause bladder cancer in humans.
Reproduction toxicity
A study of uncertain relevance reports that MDA injected into the yolks of fertile
eggs reduces hatching frequency and has teratogenic effects (25).
Dose-effect / dose-response relationships
There are no data from which to derive a dose-effect or dose-response relationship
for occupational exposure to MDA. An injection of 2-10 mg/kg given to rats
resulted in enzyme induction, but no toxic effects (57). In the NTP study, the
highest dose without toxic effect was 100 mg MDA-2HCl/liter (≈ 6-7 mg/kg for
rats, 13-16 mg/kg for mice) for 13 weeks (40).
Effects on rats and mice are summarized in Tables 1 and 2.
9Table 1. Dose-effect relationships observed in laboratory animals exposed to MDA. (i.p
= intraperitoneal; p.o. = per os; d.w. = as MDA dihydrochloride in drinking water)
Exposure method,
dose (mg/kg b.w.)
Effects Ref.
Rats
single dose, i.p.
2 or 10 No effect. 57
50 or 100 Increased enzyme activity in livers. 57
single dose, p.o.
25 Increased serum-alanine aminotransferase activity and liver weight. 2
50 Six hours after exposure: severe necrosis in intrahepatic bile ducts,
moderate damage to smaller ducts.
30
75 or 125 or 225 Increased serum-alanine aminotransferase and γ -glutamyl
transferase activity; dose-dependent increases in total serum
bilirubin and liver weights; reduced bile flow.
2
100 Necrosis and neutrophil infiltration in bile ducts, hepato-cellular
necrosis, neutrophil infiltration in parenchyme.
2
250 4 hours after exposure: severe cellular necrosis in main bile duct,
minimal damage in peripheral ducts.
24 hours after exposure: hepatocellular necrosis, cytolysis of cortical
thymocytes, bile stasis.
29
multiple doses, i.p.
2 (daily, 3 days) Increased enzyme activity in liver. 57
50 (daily, 3 days) Reduced cytochrome P450 activity, increased enzyme activity in
liver.
57
multiple doses, p.o.
20 or 50 (daily, 3 days) DNA adducts. 55
8-600 (daily, 10 days) Necrotic inflammation in gall bladders and bile ducts. 19
150 or 2001 (daily, 14 days) Hypertrophy in adrenals, thyroids and uterus of ovarectomized
females.
54
0.1% MDA in diet,
   (8 to 40 weeks)
Time-dependent increase of proliferation, necrosis and fibrosis in
bile duct epithelium and infiltration of oval cells. Reduced weight
gain.
17
38 (daily, 5 days/week,
   17 weeks)
Cirrhosis. 39
50 or 1002 mg/l, d.w.
   (13 weeks)
No effect. 40
200 mg/l, d.w. (13 weeks) Reduced water intake. 40
400 mg/l, d.w. (13 weeks) Some rats had hyperplasia in bile ducts, hypertrophy in pituitary,
hyperplasia in thyroid.
40
800 mg/l, d.w. (13 weeks) All rats had hyperplasia in bile ducts, hypertrophy in pituitary,
hyperplasia in thyroid and reduced weight gain.
40
Mice3
25 or 50 or 1004 mg/l
   (13 weeks)
No effect. 40
200 mg/l (13 weeks) Reduced weight gain. 40
400 mg/l (13 weeks) Hyperplasia in bile ducts. 40
150-300 mg/l (104 weeks) Kidney damage with mineralization of renal papillae. 56
1the animals were given MDA dihydrochloride.
2
≈ 6-7 mg/kg.
3All exposures in mice are to MDA dihydrochloride in drinking water.
4
≈13-16 mg/kg b.w.
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Table 2. Occurrence of tumors in rats and mice, 50 males or 50 females per group,
exposed to MDA dihydrochloride in drinking water for 2 years (56). The numbers in the
last two columns give the number of affected animals in the group of 50.
Species, Tumors   No. affected animals
exposure males females
Rats (Fischer-344)
Unexposed controls Liver:
  hepatocellular neoplastic nodules 1 4
Thyroid:
  follicular hyperplasia
  adenoma
  carcinoma
1
1
0
1
0
0
150 mg/l
(9-10 mg/kg/day)
Liver:
  hepatocellular neoplastic nodules 12* 8
300 mg/l
(16-19 mg/kg/day)
Liver:
  hepatocellular neoplastic nodules 25* 8
Thyroid:
  follicular hyperplasia
  adenoma
  carcinoma
2
3
7*
3
17*
2
Mice (B6C3F)
Unexposed controls Liver:
  hepatocellular adenoma
  carcinoma
7
10
3
1
Thyroid:
  follicular hyperplasia
  adenoma
  carcinoma
0
0
0
0
0
0
150 mg/l
(19-25 mg/kg/day)
Liver:
  hepatocellular adenoma
  carcinoma
10
33*
9
6
300 mg/l
(43-57 mg/kg/day)
Reduced survival
Liver:
  hepatocellular adenoma
  carcinoma
8
29*
12*
11*
Thyroid:
  follicular hyperplasia
  adenoma
  carcinoma
18*
16*
0
23*
13*
3
*significant difference from controls; p < 0.002.
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Conclusions
There are insufficient human data for establishing a critical effect of MDA.
Occupational exposure to MDA, where skin absorption plays a major role, has
caused liver damage. Judging from animal experiments, the critical effect is liver
damage, including liver cancer. MDA is genotoxic in vitro and forms DNA
adducts in vivo. MDA is carcinogenic to experimental animals and should be
regarded as carcinogenic to humans. MDA in direct contact with the skin is
readily absorbed, and the substance can cause contact allergy.
References
1. ACGIH. Documentation of the Threshold Limit Values and Biological Exposure Indices. 6th
ed. Cincinnati, Ohio: American Conference of Governmental Industrial Hygienists,
1992:998-1001.
2. Bailie MB, Mullaney TP, Roth RA. Characterization of acute 4,4´-methylene dianiline
hepatotoxicity in the rat. Environ Health Perspect 1993;101:130-133.
3. Bastian PG. Occupational hepatitis caused by methylenedianiline. Med J Aust 1984;141:533-
535.
4. Baur X, Seemann U, Marcynski B, Chen Z, Raulf-Heimsoth M. Humoral and cellular
immune responses in asthmatic isocyanate workers: report of two cases. Am J Ind Med
1996;29:467-473.
5. Brooks LJ, Neale JM, Pieroni DR. Acute myocardiopathy following tripathway exposure to
methylenedianiline . JAMA 1979;242:1527-1528.
6. Brunmark P, Bruze M, Skerfving S, Skarping G. Biomonitoring of 4,4´-methylene dianiline
by measurement in hydrolysed urine and plasma after epicutaneous exposure in humans. Int
Arch Occup Health 1995;67:96-100.
7. Cocker J, Gristwood W, Wilson HK. Assessment of occupational exposure to 4,4´-
diaminodiphenylmethane (methylene dianiline) by gas chromatography-mass spectrometry
analysis of urine. Br J Ind Med 1986:43:620-625.
8. Cocker J, Boobis AR, Davies DS. Determination of the N-acetyl metabolites of 4,4´-
methylene dianiline and 4,4´-methylene-bis(2-chloroaniline) in urine. Biomed Environ Mass
Spec 1988;17:161-167.
9. Cocker J, Nutley BP, Wilson HK. A biological monitoring assessment of exposure to
methylene dianiline in manufacturers and users. Occup Environ Med 1994;51:519-522.
10. Cohen SR. Yellow staining caused by 4,4´-methylenedianiline exposure: occurrence among
molded plastic workers. Arch Dermatol 1985;121:1022-1027.
11. Cragle DL, Wells SM, Tankersley WG. An occupational morbidity study of a population
potentially exposed to epoxy resins, hardeners and solvents. Appl Occup Environ Hyg
1992;7:826-834.
12. Dalene M, Jakobsson K, Rannug A, Skarping G, Hagmar L. MDA in plasma as a biomarker
of exposure to pyrolysed MDI-based polyurethane: correlations with estimated cumulative
dose and genotype for N-acetylation. Int Arch Occup Environ Health 1996;68:165-169.
13. Dalene M, Skarping G, Lind P. Workers exposed to thermal degradation products of TDI-
and MDI-based polyurethane: biomonitoring of 2,4-TDA, 2,6-TDA and 4,4´-MDA in
hydrolyzed urine and plasma. Am Ind Hyg Assoc J 1997;58:587-591.
14. EU 1967: Council directive 67/548/EEC on the approximation of laws, regulations and
administrative provisions relating to the classification, packaging and labelling of dangerous
substances. Annex 1. (most recent edition 010824).
12
15. Estlander T, Keskinen H, Jolanki R, Kanerva L. Occupational dermatitis from exposure to
polyurethane chemicals. Contact Dermatitis 1992;27:161-165.
16. Fairhurst S, South D, Williams C, Cocker J, Brown R. 4,4´-Methylene dianiline. Criteria
Document for an Occupational Exposure Limit. Health and Safety Executive, HSE Books,
Sheffield, United Kingdom, 1993.
17. Fukushima S, Shibata M, Hibino T, Yoshimura T, Hirose M, Ito N. Intrahepatic bile duct
proliferation induced by 4,4´-diaminodiphenylmethane in rats. Toxicol Appl Pharmacol
1979;48:145-155.
18. Von Gailhofer G, Ludvan M. The significance of patch test results to methylenedianiline.
Dermatosen 1989;37:16-18. (in German, English summary)
19. Gohlke R, Schmidt P. 4,4´-Diaminodiphenylmethane: histological, enzyme-histochemical
and autoradiographic investigation in acute and subacute experiments in rats with and without
additional heat stress. Int Arch Arbeitsmed 1974;32:217-231.
20. Hall AJ, Harington JM, Waterhouse JAH. The Epping jaundice outbreak: a 24-year follow
up. J Epidemiol Community Health 1992;46:327-328.
21. Health Council of the Netherlands: Dutch Expert Committee on Occupational Standards
(DECOS). 4,4´-Methylene dianiline. Health-based Calculated Occupational Cancer Risk
Values. The Hague: Health Council of the Netherlands, 2000, 2001/11OSH.
22. Hewitt PG, Hotchkiss SAM, Caldwell J. Decontamination procedures after in vitro topical
exposure of human and rat skin to 4,4´-methylenebis(2-chloroaniline) and
4,4´methylenedianiline. Fundam Appl Toxicol 1995;26:91-98.
23. Hofman HT, Frohberg H, Meinecke KH, Oettel H, von Schilling B, Zeller H. Potential
injuries by 4,4´-diaminodiphenylmethane: earlier recognition and prevention. Proceedings of
the Fifteenth International Conference of Occupational Health. 1966;11-2:849-851. (in
German)
24. Hofman HT, Frohberg H, Meinecke KH, Oettel H, von Schilling B, Zeller H. Zur Toxicität
von 4,4´-Diaminodiphenylmethan. Naunyn Arch Pharmacol 1966;253:47. (in German)
25. IARC. Some chemicals used in plastic and elastomers. 4,4´-Methylenedianiline and its
dihydrochloride. IARC Monographs on theEvaluation of Carcinogenic Risks to Humans.
Lyon: International Agency for Research on Cancer 1986;39:347-365.
26. IARC. Overall evaluations of carcinogenicity: an updating of IARC Monographs volumes 1
to 42. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Lyon:
International Agency for Research on Cancer 1987;suppl. 7:66.
27. Kajbaf M, Sepai O, Lamb JH, Naylor S. Identification of metabolites of 4,4´-
diaminodiphenylmethane (methylene dianiline) using liquid chromatographic and mass
spectrometric techniques. J Chromatogr 1992;583:63-76.
28. Kanerva L, Jolanki R, Estlander T. Allergic and irritant patch test reactions to plastic and glue
allergens. Contact Dermatitis 1997;37:301-302.
29 Kanz MF, Wang A, Campbell GA. Infusion of bile from methylene dianiline-treated rats into
the common bile duct injures biliary epithelial cells of recipient rats. Toxicol Lett
1995;78:165-171.
30. Kanz MF, Gunasena HG, Kaphalia L, Hammond KL, Syed YA. A minimally toxic dose of
methylene dianiline injures biliary epithelial cells in rats. Toxicol Appl Pharmacol
1998;150:414-426.
31. Kautiainen A, Wachtmeister CA, Ehrenberg L. Characterization of hemoglobin adducts from
a 4,4´-methylenedianiline metabolite evidently produced by peroxidative oxidation in vivo.
Chem Res Toxicol 1998;11:614-621.
32. Kopelman H, Robertson MH, Sanders PG, Ash I. The Epping jaundice. Brit Med J
1966;1:514-516.
33. Kopelman H, Scheuer PJ, Williams R. The liver lesion of the Epping jaundice. Quarterl J
Med, New series 1966;XXXV:553-564.
13
34. LeVine MJ. Occupational photosensitivity to diaminodiphenylmethane. Contact Dermatitis
1983;9:488-490.
35. Liss GM, Guirguis SS. Follow-up of a group of workers intoxicated with 4,4´-
methylenedianiline. Am J Ind Med 1994;26:117-124.
36. Lundberg P (ed). Scientific Basis for Swedish Occupational Standards. VIII. 4,4´-Methylene
dianiline and its dihydrochloride. Arbete och Hälsa 1987;39:165-172. National Institute of
Occupational Health, Solna.
37. McGill DB, Motto JD. An industrial outbreak of toxic hepatitis due to methylenedianiline. N
Engl J Med 1974;291:278-282.
38. McQueen CA, Williams GM. Review of the genotoxicity and carcinogenicity of 4,4´-
methylene-dianiline and 4,4´-methylene-bis-2-chloroaniline. Mutat Res 1990;239:133-142.
39. Munn A. Occupational bladder tumors and carcinogens: recent developments in Britain. In:
Deichmann W, Lampe K, eds. Bladder Cancer, A Symposium. Birmingham: AL,
Aesculapius, 1967: 187-193.
40. NTP. Technical Report 248, on the carcinogenesis bioassay of 4,4´-methylenedianiline
dihydrochloride in F344/N rats and B6C3F/N mice. Research Triangle Park, N.C.: National
Toxicology Program, 1983. Report No. 83-2504.
41. Parodi S, Taningher M, Russo P, Pala M, Tamaro M, Monti-Bragadin C. DNA-damaging
activity in vivo and bacterial mutagenicity of sixteen aromatic amines and azo-derivatives, as
related quantitatively to their carcinogenicity. Carcinogenesis 1981;2:1317-1326.
42. Parodi S, Zunino A, Ottaggio L, De Ferrari M, Santi L. Lack of correlation between the
capability of inducing sister-chromatid exchanges in vivo and carcinogenic potency, for 16
aromatic amines and azo derivatives. Mutat Res 1983;108:225-238.
43. Pludro G, Kartlowski K, Mankowska M, Woggon H, Uhde W-J. Toxicological and chemical
studies of some epoxy resins and hardeners. I. Determination of acute and subacute toxicity
of phthalic acid anhydride, 4,4´-diaminodiphenylmethane and of the epoxy resin: Epilox EG-
34. Acta Pol Pharmacol 1969;26:352-357.
44. Roy CW, McSorley PD, Syme JG. Methylene dianiline: a new toxic cause of visual failure
with hepatitis. Human Toxicol 1985;4:61-66.
45. Rudzki E, Rebandel P, Zawadzka A. Sensitivity to diaminodiphenylmethane. Contact
Dermatitis 1995;32:303-317.
46. Schoental R. Carcinogenic and chronic effects of 4,4´-diaminodiphenylmethane, an epoxy
resin hardener. Nature 1968;219:1162-1163.
47. Schütze D, Sepai O, Lewalter J, Miksche L, Henschler D, Sabbioni G. Biomonitoring of
workers exposed to 4,4´-methylenedianiline of 4,4´-methylenediphenyl diisocyanate.
Carcinogenesis 1995;16:573-582.
48. Schütze D, Sagelsdorff P, Sepai O, Sabbioni G. Synthesis and quantification of DNA adducts
of 4,4´-methylenedianiline. Chem Res Toxicol 1996;9:1103-1112.
49. Seldén A, Berg P, Jakobsson R, de Laval J. Methylene dianiline: assessment of exposure and
cancer morbidity in power generator workers. Int Arch Occup Environ Health 1992;63:403-
408.
50. Sepai O, Schütze D, Heinrich U, Hoymann HG, Henschler D, Sabbioni G. Hemoglobin
adducts and urine metabolites of 4,4´-methylenedianiline after 4,4´-methylenediphenyl
diisocyanate exposure of rats. Chem Biol Interact 1995;97:185-198.
51. Steinhoff D, Grundmann E. Carcinogenic activity of 4,4´-diaminophenyl methane and 2,4´-
diaminodiphenylmethane. Naturwissenschaften 1970;57:247-248.
52. Tanaka K, Ino T, Sawahata T, Marui S, Igaki H, Yashima H. Mutagenicity of N-actyl and
N,N´-diacetyl derivatives of 3 aromatic amines used as epoxy-resin hardeners. Mutat Res
1985;143:11-15.
53. Tillman HL, van Pelt FNAM, Martz W, Luecke T, Welp H, Dörries F, Veuskens A, Fischer
M, Manns MP. Accidental intoxication with methylene dianiline p,p´-diaminodiphenyl-
14
methane: acute liver damage after presumed ecstasy consumption. Clin Toxicol 1997;35:35-
40.
54. Tullner WW. Endocrine effects of methylenedianiline in the rat, rabbit and dog.
Endocrinology 1959;66:470-474.
55. Vock EH, Hoymann HG, Heinrich U, Lutz WK. 32P-Postlabeling of a DNA adduct derived
from 4,4´-methylenedianiline, in the olfactory epithelium of rats exposed by inhalation to
4,4´-methylenediphenyl diisocyanate. Carcinogenesis 1996;17:1069-1073.
56. Weisburger EK, Murthy ASK, Lilja HS, Lamb JC. Neoplastic response of F344 rats and
B6C3F mice to the polymer and dyestuff intermediates 4,4´-methylenebis(N,N-dimethyl)-
benzenamine, 4,4´-oxydianiline, and 4,4´methylenedianiline. J Natl Cancer Inst
1984;72:1457-1461.
57. Wu K, Leslie CL, Stacey NH. Effects of mutagenic and non-mutagenic aniline derivatives on
rat liver drug-metabolizing enzymes. Xenobiotica 1989;19:1275-1283.
58. Zylbersac S. Action cirrhogène des diamino-diphényles insollubles sur le foie du rat. Cr Soc
Biol 1951;145:136-138. (in French)
15
Consensus Report for Methylisocyanate
(MIC) and Isocyanic Acid (ICA)
December 5, 2001
Chemical and physical data. Occurrence
methylisocyanate (MIC) isocyanic acid (ICA)
CAS No.: 624-83-9 75-13-8
Synonyms: isocyanic acid methylester hydrogen isocyanate
Structure: H3C-N=C=O HN=C=O
Molecular weight: 57.06 43.02
Boiling point: 39 °C 23 °C
Melting point: - 45 °C - 80 °C
Vapor pressure: 46.4 kPa (20 °C) 13.3 kPa (- 19 °C)
Conversion factors: 1 ppm = 2.4 mg/m3 1 ppm = 1.8 mg/m3
1 mg/m3 = 0.4 ppm 1 mg/m3 = 0.6 ppm
Methylisocyanate (MIC) is a monoisocyanate. At room temperature it is a clear
liquid. MIC is sparingly soluble in water, although on contact with water it reacts
violently, producing a large amount of heat. The speed of the reaction depends a
great deal on temperature, and is accelerated by acids, bases and amines (50).
MIC has a sharp odor and an odor threshold above 2 ppm (13). Isocyanic acid
(ICA) above 0 °C is an unstable liquid with a tendency to polymerize. The
primary polymerization product – which is also generated in gas form – is the
trimer, cyanuric acid. Isocyanic acid is soluble in water, but disintegrates both via
ionization and by formation of ammonia and carbon dioxide (10). In gas form it
has a sharp odor (54).
Methylisocyanate occurs primarily as an intermediate in the production of
carbamate pesticides. It has also been used in the production of polymers (32).
Photolytic breakdown of N-methyldithiocarbamate releases some MIC, and it can
therefore occur in the air around application of the pesticides (26). MIC is found
in tobacco smoke: the measured content in the main stream ranges from 1.5 to
5 µg per cigarette (33). In the laboratory, MIC has also been identified in
emissions from heating of core sand and mineral wool, where it results from
breakdown or chemical transformation of the carbamide resin binder (42, 46).
Exposure measurements made in foundries indicate that MIC occurs primarily
where “hot box” cores are used in chill casting (47). MIC occurs in the isocyanate
mixture created by thermal breakdown of TDI- or HDI-based polyurethane
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lacquers during welding, cutting and grinding operations in automobile repair
shops (7, 59). ICA is usually found along with MIC in welding plumes (and also
around chill casting), often in concentrations as much as ten times as high. Most
information on the occurrence of MIC and ICA is relatively new, since it has only
recently become possible to analyze low-molecular monoisocyanates in mixed
chemical exposures such as those resulting from thermal breakdown. A method
based on sampling in dibutyl amine followed by analysis with liquid chroma-
tography-mass spectrometry (LC-MS) (42) was published in 1998. Several
laboratories have since developed methods for analyzing MIC. In another method
that has been found applicable, samples are derivatized with 1-(2-methoxy-
phenyl)piperazine and analyzed using GC-MS; LC and other detectors have also
been used successfully (20). A recently published abstract presents a diffusion
sampling method for MIC (48). These methods can also be used for analysis of
ICA. Because of its instability, however, ICA is not commercially available – a
circumstance that makes its quantification difficult.
Uptake, biotransformation, excretion
Massive exposure to MIC was one of the consequences of the disaster in Bhopal,
India, in 1984, when about 27 tons of MIC dispersed into a populated area around
a Union Carbide plant. There are no precise air measurements, but concentrations
were later estimated to have been in the range 0.12 to 85 ppm (17). In subsequent
assessments of the injuries, it has been debated whether they were caused in-
directly as a result of reduced respiratory function or directly via respiratory
uptake and distribution to other organs (13). The question arises from the fact that
MIC is a powerful irritant: it is postulated that this may have inhibited normal
respiratory uptake and systemic distribution. After Bhopal, animal experiments
with radiocarbon-labeled MIC were conducted to clarify this point.
Mice were exposed by inhalation to 0.5, 5 or 15 ppm 14C-MIC for 1 to 6 hours,
and uptake and distribution were studied (24). The radioactivity appeared in the
blood within a few minutes, but did not show a linear increase with concentration.
This was attributed to the greater irritation of higher doses and the resulting
formation of mucus in the respiratory passages, which was assumed to affect the
respiratory rate and thus inhibit inhalation and uptake in the blood. The highest
radioactivity in blood in relation to air concentration was measured after the
exposure to 0.5 ppm. Radioactivity in blood dropped gradually after the exposures
and was nearly gone within three days. Radioactivity fell more rapidly in urine
than in bile. In male mice, the highest levels of radioactivity after 2 hours were
found in the lungs, sternum, digestive tract, spleen and kidneys, and after 24 hours
in blood and lungs. In female mice, the highest levels of radioactivity after 2 hours
were in lungs, fetuses, spleen, uterus and kidneys, and after 24 hours in lungs,
spleen and fetuses (24). The effective uptake and distribution is probably due to
the in vivo binding of MIC to proteins in tissues, blood plasma and erythrocyte
membranes. Protein binding has been experimentally verified in mice after both
inhalation and intraperitoneal administration of 14C-labeled MIC (11, 12).
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Sax (55) mentions, without going into detail, that MIC is absorbed by the skin.
No other data on skin uptake were found.
MIC has been observed to cause carbamoylation of N-terminal valine in the
hemoglobin of rats and rabbits both in vivo and in vitro (53), and 3-methyl-5-
isopropyl hydantoin (MIH), the cyclic transformation product of MIC and valine,
could then be identified in blood. MIH has also been identified in blood from the
Bhopal victims (61). S-(N-methylcarbamoyl)glutathione, another reactive
conjugate, has been identified in bile from rats given MIC via a catheter in the
portal vein (52). In another experiment, the glutathione conjugate in the form of
S-(N-methylcarbamoyl)-N-acetylcysteine was identified in urine of rats given
MIC intraperitoneally (60).
MIC reacts readily with water, forming methylamine, which further reacts to
dimethylurea (72). It is quite likely that some MIC is also transformed in vivo to
methylamine. No studies were found in which methylamine or dimethyl urea were
measured in blood or urine, however.
There is no information on uptake, biotransformation or excretion of ICA.
Patients with uremia have elevated concentrations of carbamoylated hemoglobin,
which is the reaction product of hemoglobin and isocyanic acid (45, 73). The
isocyanic acid is assumed to result from the endogenous breakdown of urea
occurring in cases of acute kidney failure.
Toxic effects
Human data
A study made at an industry producing and using MIC presents an examination of
lung function data in employee medical records covering a 10-year period (the
dates are not given) (8). The employees were divided by their supervisors into
four categories based on their estimated exposure to MIC: none (N = 123), low
(N = 103), moderate (N = 138) and high (N = 67). The records also contained in-
formation on smoking habits. About 800 monitoring measurements of MIC (the
method used is not reported) had been made in the 1977 – 1990 period. In 1977
more than 80% of the measurements had exceeded 0.02 ppm, whereas only one
of 33 measurements made in 1990 were above this level. The groups were
compared, using lung function values from the most recent examination and
taking smoking habits into account, and no effect of MIC on lung function could
be discerned. Nor was any effect seen when a worker’s first examination was
compared with his most recent one. Conclusions should be drawn with caution,
however, since individuals who developed health problems may have quit (and
thus not been examined after the problem arose) and also because there is
considerable room for error in the exposure classifications. The medical records
also contained information on exposures due to spills or leakage. The authors do
not give the number of these cases, but report that the most common symptoms
were eye and skin irritation, and in a few cases respiratory problems. No clear
effect on lung function was seen in these cases.
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Four volunteers were briefly exposed (1 to 5 minutes) to MIC (44) (see Table
1). No effect was noted at an exposure level of 0.4 ppm, but 2 ppm caused
irritation of eyes (notably tear flow) and mucous membranes in nose and throat,
although no odor was perceived. At 4 ppm the symptoms of irritation were more
pronounced, and at 21 ppm they were unbearable.
There are several studies providing information on the 1984 disaster in Bhopal.
About 200,000 persons were acutely exposed to high (> 27 ppm) concentrations
of MIC, as well as to other substances including phosgene, methylamine and
hydrogen cyanide (50). There is thus some doubt as to whether all the observed
effects can be attributed to MIC. Because of the nature of the exposure conditions,
and because effects on the lungs may have produced secondary effects on other
organs, most of the toxicological information from the disaster is of little value in
establishing an occupational exposure limit. A brief review of some of the studies
is nevertheless presented below.
The acute effects of the Bhopal disaster have been compiled. It is estimated that
about 2000 people died within the first few hours. The reported cause of death is
alveolar necroses combined with ulcerations in bronchial mucosa and pulmonary
edema (71). In one study, 379 survivors were divided into eight groups on the
basis of their degree of exposure, as estimated from the numbers of dead (both
humans and animals) near their homes and the hypothetical spread of the toxic
cloud. There were 119 controls with similar socioeconomic backgrounds. The
number of dead was estimated to be 1850 in an area that was assumed to represent
70% of the total area contaminated by the gas. The symptom most commonly
reported on the questionnaire given to the surviving victims was smarting eyes,
followed by coughing, persistent tear flow and nausea. The prevalence of eye
symptoms showed no correlation to the proportion of deaths nearby, but the
reports of coughing did show such a correlation. Redness and superficial sores
on corneas and conjunctiva were observed in eye examinations (5). Since amines
can cause eye damage (35), the relevance of MIC here can not be assessed with
certainty.
Kamat et al. (41) followed 113 patients who had been referred to their
pulmonary medicine and psychiatric clinics for persistent respiratory symptoms in
the three months following the disaster. The patients (with 23 - 50% attrition from
the original cohort) were followed up at 3, 6, 12, 18 and 24 months, using a
standardized questionnaire, physical examinations, lung x-rays, spirometry etc.
The report is difficult to interpret, but it appears that a patient’s condition was
initially classified on the basis of the number and severity of respiratory
symptoms: mild for 30 patients, moderate for 57, and severe for 26. The respira-
tory symptoms had regressed somewhat at 3, 6, and 12 months, but increased
again at 18 and 24 months. Shortness of breath with physical exertion was the
most persistent. Neurological symptoms such as muscular weakness and forget-
fulness increased. The proportion of patients with depression had increased at
6 months and the proportion with anxiety at 12 months. Other symptoms, such
as irritability and concentration difficulty, showed declining trends. Only 2 to
4 percent of the lung x-rays were judged to be completely normal. The others
19
showed changes in interstitial lung tissue and in the pleural sac. Lung function
tests revealed possible reductions in lung function, primarily of a restrictive type.
The above study also presents an analysis of antibodies in serum samples from
99 cases (41). These results are more fully described in an earlier report from the
same study (43). The initial samples were taken a few months after the disaster,
and MIC-specific antibodies were found in 11 subjects: IgM in 7, IgG in 6 and
IgE in 4. The antibody titers of some of the subjects were followed for up to a
year after the disaster. The rises in antibodies were small, and in most cases later
samples were negative. The small elevations in IgE antibodies were seen only on
the first sampling occasion (41, 43). The data on antibodies are difficult to assess,
since the documentation is poor and the articles contain inconsistencies.
Another research group made similar examinations of lung function in Bhopal
victims one to seven years after the disaster (70). The material consisted of 60
persons, 6 of whom were judged to have had low exposure (slight irritation of
eyes and respiratory passages on the day of the disaster), 13 moderate exposure
(respiratory symptoms, eye irritation that did not require hospitalization), and 41
high exposure (respiratory and eye symptoms severe enough to require
hospitalization and/or death of a family member as a result of the exposure).
There was also an unexposed control group. The most commonly reported
symptoms were shortness of breath on physical exertion and coughs. BAL
samples taken one to seven years (average 2.8 years) after the disaster showed
elevations of total cell counts, macrophages and lymphocytes in the high-exposure
group, statistically significant when compared with the low-exposure group and
controls.
Permanent damage to the respiratory passages was reported in a follow-up
study made 10 years after the disaster (16). Questionnaires were distributed to 454
persons chosen on the basis of residence within a radius of 2, 4, 6, 8 or 10 kilo-
meters from the plant. The control group comprised persons of the same socio-
economic background who lived in an area outside the city. From the cohort, 20%
were randomly chosen for spirometry tests; this group ultimately contained 74
persons. The occurrence of specific respiratory symptoms – mucus formation,
cough, rales etc. – could be clearly related to the exposure level derived from the
distance between the victim’s home and the site of the disaster (from 0-2 km to
>10 km). The symptoms were equally prevalent among men and women, and
more common among persons below 35 years of age (median value for the entire
group) and among smokers than non-smokers. The same trend could be discerned
in the results of lung function tests, which showed mild obstructive reductions in
lung function that increased with proximity to the plant. This trend became a bit
less clear when smoking habits and socioeconomic factors were included in the
calculations.
In a follow-up study of effects on eyes, no cases of blindness or impaired vision
were found 2 months after the event (6). Of a total of 131 examined cases, six had
unilateral scars on the cornea, three had corneal edema and one complained of
constantly running eyes. After 3 years, 463 were examined, 99 of whom were
controls. Compared with controls, the victims of the Bhopal disaster had higher
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frequencies of eye irritation, eyelid infections, cataracts, trachoma and loss of
visual acuity, which increased with increasing exposure (4).
One year after the disaster, a study of cognitive function was made on a group
of 52 victims (51). They were grouped into three exposure classes on the basis of
symptoms and distance from the plant. Compared with controls, normal per-
formance values were seen in the least-exposed group, whereas in the other two
groups the values deviated significantly for “associate learning” and motor
ability. In the most exposed group there were also lower values on the Standard
Progressive Matrix (SPM), a test that measures ability to think logically. Clinical
indications of central, peripheral and vestibular neurological damage, as well as
impaired short-term memory, were also seen in another study of the Bhopal
victims (15). In interviews, they reported more psychological symptoms such as
headaches, fatigue, concentration difficulty and irritability than controls. The
symptoms did not always increase with exposure. The exposure estimates can be
questioned in both these studies of CNS effects, and in the latter article there is
some discussion of the difficulty of taking socioeconomic differences into account
in assessing the results. The authors also suggest that persistent depressions may
be a factor contributing to the other symptoms.
Asthma resulting from exposure to MIC has not been reported.
For ICA, there are no data regarding toxic effects on humans.
Animal data
The calculated LD50 for rats given MIC subcutaneously is 329 mg/kg body
weight. The LC 50 for 30 minutes of exposure was 465 ppm (1080 mg/m3) (38).
The LC50 for 15 minutes of exposure to MIC has been reported to be 171 ppm for
rats and 112 ppm for guinea pigs (19). The reported LC50 for 3 hours of exposure
is 26.8 ppm for mice (68).
The RD50 for mice (the dose that causes a 50% decline in respiratory rate), a
measure of sensory irritation (effects on the trigeminus nerve via the upper
respiratory passages), was estimated to be 1.3 ppm in one study (23), and 2.9 ppm
in another (34). The RD50 for pulmonary irritation (stimulation of the vagus nerve
cells via type J receptors in the alveoli) was 1.9 ppm for mice exposed via tracheal
catheters (23).
Irritation of the upper and lower respiratory passages is the most commonly
reported effect in all animal experiments. When rats were exposed to 0, 3, 10 or
30 ppm MIC for 2 hours, effects on lung function increased with concentration.
No abnormal changes of lung function were observed at exposure to 3 ppm MIC,
but exposure to 10 ppm caused obstructive changes in respiratory passages which
did not regress during the following 13 weeks (62). Lung damage was seen in rats
exposed to 3 or 10 ppm MIC for 2 hours and examined 4 and 6 months later. At 4
months there were ECG changes in both dose groups, and right ventricular hyper-
trophy was also seen in the high-dose group (not examined at 6 months). The
authors suggest that the hypertrophy and the ECG changes were probably
secondary effects of the lung damage with pulmonary hypertension (63). A
LOAEL (Lowest Observed Adverse Effect Level) of 3.1 ppm for damage to
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respiratory epithelium was reported in a study in which rats were exposed by
inhalation to 0, 0.15, 0.6 or 3.1 ppm MIC 6 hours/day for 4 + 4 days. The NOAEL
(No Observed Adverse Effect Level) in this study was 0.6 ppm (18).
Six hours of high exposure – above 4.4 ppm for guinea pigs, above 4.6 ppm for
rats and above 8.4 ppm for mice – resulted in damage to the upper respiratory
passages of all three species: necrosis and erosion of epithelial cells in the larynx
and trachea, and alveolitis, hemorrhages and inflammation in lungs (25). The
changes disappeared within a week. When rats were exposed to 128 ppm
(320 mg/m3) MIC 8 minutes/day for 10 days, the exposure induced progressive
cellular inflammation with increase of eosinophils, neutrophils and mononuclear
cells (28). Guinea pigs exposed for 3 hours to 19 or 37 ppm MIC had lung
changes of the same types reported earlier in the victims at Bhopal (22).
In one study (14), F344 rats and B6C3F1 mice were exposed by inhalation to 0,
1, 3 or 10 ppm MIC for 2 hours, and then observed for 2 years. Survival and
weight gain were normal in all exposure groups. Definite effects on the lungs,
particularly proliferation of the connective tissue layer below the respiratory
epithelium and connective tissue invasion in the lumen of the respiratory
passages, were observed in the rats exposed to 10 ppm. Similar damage was seen
in another group of rats exposed to 10 ppm MIC and examined one year later.
Rats and mice exposed to 10 or 30 ppm MIC for 2 hours had severe necrosis
and damage on most of the nasal mucosa, including the olfactory cells. Both
epithelial and olfactory cells regenerated rapidly, however, and had returned
to normal within 3 months (66).
In a National Toxicology Program (NTP) study (31), mice were exposed to 1
or 3 ppm MIC 6 hours/day for 4 days. Histopathological examination after the
exposure to 3 ppm revealed pronounced fibrosis in bronchi, with intraluminal
fibrosis and damage to olfactory epithelium. The 1 ppm exposure caused damage
to respiratory epithelium (not more fully described). Myelotoxic effects on stem
cells were also observed at both exposure levels, but they were judged to be a
secondary effect of the damage to the respiratory system.
Immunological effects of MIC have been examined in some studies (43, 65).
A slight increase of immunoglobulin levels was measured in rats after exposure to
MIC (56). MIC demonstrated a slight immunosuppressive effect in an NTP study
with mice (65). Mice were exposed to 1 or 3 ppm MIC 6 hours/day for 4 days, and
slightly reduced mitogen-stimulated lymphocyte proliferation was observed at
both doses; at the higher dose there was also a significantly lower response on
MLR (Mixed Leukocyte Response) tests. The reduction was temporary and had
disappeared after 120 days. The authors regard these effects as secondary,
resulting from toxic effects on the lungs or general toxicity, rather than a direct
effect of MIC on the immune system.
Systemic effects of MIC observed in exposed rats are severe hyperglycemia,
metabolic acidosis and uremia (11, 36, 38). Exposure of mice or rats to MIC
concentrations in the range 3 to 30 ppm, either intraperitoneally or via inhalation,
has caused temporary degenerative changes in blood cells and cells in liver
parenchyma (29). In a study with mice, intraperitoneal injections of 293-1170 mg
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MIC/kg body weight had effects on amino acid concentrations (stimulating on
glutamate and aspartate, inhibiting on GABA) in the brain and plasma. This was
regarded as an indication of neurotoxic and systemic effects (30). In vitro studies
have shown that MIC affects both brain and muscle cells, but the clinical rele-
vance of this finding is not clear (2, 3).
There are only a few studies of the toxic mechanisms of MIC. In vitro and in
vivo studies with cells from hepatic and nervous tissue of rats indicate that MIC
can inhibit the respiratory chain in mitochondria, and thus induce histotoxic hy-
poxia (39, 40). This effect was also observed in another study, in which guinea
pigs were exposed to 25, 125 or 225 ppm and rats to 100, 600 or 1000 ppm MIC
for 15 minutes (64). MIC also exerts a dose-dependent inhibition of acetyl-
cholinesterase activity in vitro in erythrocytes from humans, rats and guinea pigs
(37, 64).
There are no data from animal studies on toxic effects of ICA.
Mutagenicity, carcinogenicity, teratogenicity
MIC showed no mutagenic activity in standard Ames’ tests (58). Negative
results were also obtained in Ames’ tests with urine from rats exposed to MIC (1)
and in a sex-linked recessive lethal test with Drosophila (58). In the same study,
positive results were obtained for point mutations in the mouse lymphoma test.
The authors conclude that MIC may be genotoxic by binding to nuclear proteins.
MIC has induced chromosome aberrations and polyploidy in hamster fibroblasts
both with and without metabolizing systems (49). Persons exposed to MIC and
other substances during the Bhopal disaster had higher frequencies of
chromosome aberrations than unexposed controls (27).
No neoplastic changes in respiratory organs were observed in a study (14) in
which F344 rats and B6C3F1 mice were exposed by inhalation to 0, 1, 3 or 10 ppm
MIC for 2 hours and subsequently observed for up to 2 years. In the male rats
exposed to 3 or 10 ppm there were elevated incidences of pheochromocytomas in
adrenal cortex and acinous tumors in pancreas. This study is not a conventional
cancer study, and the authors point out that the correlation to exposure is weak
and that no conclusions should be drawn on the basis of their observations.
Judging from structure-activity correlations, the carcinogenic potency of MIC
should be low (21). There are no mutagenicity, carcinogenicity or teratogenicity
studies with long-term exposures to MIC.
A dose-dependent absorption of fetuses was observed in mice exposed to 2, 6, 9
or 15 ppm MIC for 3 hours on the eighth day of gestation. There was total resorp-
tion in more than 75% of the females exposed to the two highest doses, and
reduced fetus and placenta weights were observed at all dose levels. The authors
suggest that the maternal toxicity (weight loss, reduced weight gain) may have
caused the observed effects (67). In a later study it was shown that treatment with
hormones that counteract certain effects of the maternal toxicity (but not e.g.
weight loss) did not counteract the effects on the fetuses (69). In another study,
mice were exposed to 1 or 3 ppm MIC 6 hours/day on days 14 to 17 of gestation.
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There were significant increases in the numbers of dead fetuses in both groups,
and lower neonatal survival in the high-dose group. The authors caution against
drawing conclusions on whether the fetotoxicity was a direct effect of MIC or
was secondary to the effects on the lungs of the mothers (57).
Studies of victims of the Bhopal disaster revealed that mothers exposed to MIC
had higher numbers of miscarriages, but not stillbirths, than unexposed controls
(9). In a controlled study, Cullinan et al. (15) reported an increase in stillbirths
(exposed 9%, unexposed 4%) and miscarriages (year of disaster 7%, later years
1%), but the study covered few cases.
There are no data on mutagenicity, carcinogenicity or teratogenicity for ICA.
Dose-effect / dose-response relationships
Despite the Bhopal disaster and the facts that MIC is chemically related to more
thoroughly studied substances such as toluene diisocyanate and is an extremely
toxic substance, the literature on which to base a critical effect or a dose-response
relationship is scanty. No reliable studies on the relationship between occupational
exposure to MIC and effects on health were found. There is only one study on
dose-response relationships for humans. Results from animal studies suggest that
dose-effect and dose-response curves are steep.
Irritation of eyes and mucous membranes has been described in human subjects
after short-term exposures to MIC. In one study, volunteers were exposed to MIC
for 1 to 5 minutes: at 0.4 ppm no irritation was reported, but irritation of eyes and
mucous membranes increased markedly at 2 and 4 ppm, and was unacceptable at
21 ppm (see Table 1).
Irritation of upper and lower respiratory passages has been described in studies
with rats, mice and guinea pigs. Permanent lung damage has been reported at
higher doses (Table 2). The exposure-effect relationships observed in laboratory
animals exposed by inhalation to MIC are summarized in Table 2.
There are no data on which to base an estimate of dose-effect or dose-response
relationships for ICA.
Table 1. Effects on four volunteers exposed to MIC in an exposure chamber for 1 to 5
minutes (44).
MIC concentration Effects
21 ppm Unendurable irritation
 4 ppm Severe irritation of mucous membranes
 2 ppm Tear flow, irritation of eyes, nose and throat
 0.4 ppm No irritation
24
Table 2. Effects on laboratory animals exposed by inhalation to MIC.
Exposure Species Effect Ref.
171 ppm, 15 min. rat LC50 19
121 ppm, 15 min. guinea pig LC50 19
12.2 ppm, 6 hours mouse LC50 25
10 ppm, 2 hours rat Proliferation of connective tissue below respiratory
epithelium with intrusion into respiratory lumen
14
10 ppm, 2 hours rat Right ventricular hypertrophy, ECG changes
secondary to lung damage
63
9 ppm, 3 hours
day 8 or 9 of gestation
mouse, rat Over 80% of fetuses resorbed, reduced placenta
weights
67
6.1 ppm, 6 hours rat LC50 25
5.4 ppm, 6 hours guinea pig LC50 25
3.1 ppm, 6 hours/day,
4 + 4 days
rat Damage to respiratory epithelium, weight loss,
pulmonary edema, increase in hemoglobin (males)
18
3 ppm, 6 hours/day,
4 days
mouse Bronchial fibrosis, damage to olfactory epithelium 31
3 ppm, 2 hours rat ECG changes due to lung damage 63
3 ppm, 2 hours rat No changes in lung function 62
2.9 ppm, 30 min. mouse RD50 (sensory irritation) 34
2.4 ppm, 6 hours mouse, rat,
guinea pig
Retarded weight gain 25
1.9 ppm, 90 min.
(via tracheal catheter)
mouse RD50 (pulmonary irritation) 23
1.3 ppm, 90 min. mouse RD50 (sensory irritation) 23
1 ppm, 6 hours/day
4 days
mouse Damage to respiratory epithelium 31
0.6 ppm, 6 hours/day
4 + 4 days
rat No effect on respiratory passages,
weight or hemoglobin levels
18
25
Conclusions
Judging from the data from brief exposures of human subjects, the critical effect
of exposure to MIC is irritation of eyes and mucous membranes, which occurs at
2 ppm. In animal experiments exposure to similar levels for up to 6 hours results
in severe damage to mucous membranes in respiratory passages. At somewhat
higher levels there is a steep increase in mortality.
There are no data which would serve to establish a critical effect for ICA.
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This report is an update of the Consensus Report published in 1992 (6).
Chemical and physical data. Uses
CAS No.: 110-12-3
Synonyms: 5-methylhexane-2-one
5-methyl-2-hexanone
isoamylmethylketone
isopentylmethylketone
methyl isoamyl ketone
MIAK
Formula: CH3COCH2CH2CH(CH3)2
Molecular weight: 114.19
Boiling point: 144 °C
Melting point: - 73.9 °C
Flash point (closed cup): 43 °C
Density: 0.813 g/ml
Vapor pressure (20 °C): 0.2 kPa (6); 0.6 kPa (10)
Saturation concentration: 5900 ppm (20 °C)
Solubility in water: 5.4 g/liter
Conversion factors (20 °C): 1 mg/m3 = 0.211 ppm
1 ppm = 4.74 mg/m3
MIAK is a clear, flammable liquid with a sharp, sweetish odor. The odor
threshold has been reported to be 0.01 (11) and 0.18 ppm (3). The latter value
was calculated with QSAR (Quantitative Structure-Activity Relationship). The
substance is soluble in alcohol and ether and somewhat soluble in water (10). It
is used as a solvent for nitrocellulose, cellulose acetate, and acrylic and vinyl
copolymers (11).
Uptake, biotransformation, excretion
Uptake of MIAK via inhalation and oral administration has been studied in rats.
With six hours of inhalation exposure to 1950 ppm, the highest concentration in
blood (138 µg/ml) was measured after 4 hours, and with single oral doses of 1830
mg/kg body weight (b.w.) the highest blood concentration (94 µg/ml) was seen
30
after 1 hour. The half time in blood was 0.7 hours after the inhalation exposure
and 5.3 hours after the oral dose (5). Skin uptake is indicated by an LD50 for
dermal exposure (8), but this study provides no uptake data. The water/air
distribution coefficient for MIAK is reported to be 240 (1) and that for
octanol/water is given as 52.5 in one work (3) and as 75.9 in another (9).
Toxic effects
MIAK has fairly low acute toxicity. The reported LD50 for oral administration to
rats and mice is in the range 2542 – 4760 mg/kg b.w. (8, 9, 11), and the reported
LD50 for skin application to rabbits is 8130 mg/kg b.w. (8). An LC50 somewhere
between 2000 and 4000 ppm is reported in an inhalation study with rats (4 hours
of exposure: 0/6 rats died at 2000 ppm; 6/6 died at 4000 ppm) (8). An unpublished
study with rats (cited in Reference 10) gives a calculated LC50 of 3813 ppm for 6-
hours of exposure. The same study reports that 6-hour exposures resulted in eye
irritation, narcosis, reduced respiratory rates and a death (1/4) at 3200 ppm, effects
on the central nervous system (reduced response to noise) at 1600 ppm, and no
discernible effects at 800 ppm (10).
The RD50 (50% reduction of respiratory rate due to sensory irritation in the
upper respiratory passages) for mice exposed to MIAK by inhalation is reported in
one study to be 1232 ppm for 5 minutes (Muller & Greff 1984, cited in Reference
7). In another study, inhalation of 416 to 1515 ppm MIAK for 15 minutes was
found to reduce the respiratory rates of mice by 27 to 61%, and the RD50 was
calculated to be 1222 ppm (2). The reported nasal irritation threshold for people
exposed to MIAK, calculated with QSAR, is 2042 ppm (3).
Effects on the nervous system, measured as reduction in total duration of
inactivity during 3 minutes of swimming (the“behavioral despair swimming
test”), were reported in mice after 4 hours of whole-body exposure to 270 – 637
ppm MIAK. The lowest exposure level (270 ppm) yielded a 26% reduction in the
total duration of inactivity, and the ID50 (the air concentration causing a 50%
deterioration in test performance) was calculated to be 446 ppm (2). The relevance
of this swimming test in assessing toxicity, however, is unclear (11).
In an inhalation experiment, rats were exposed 6 hours/day, 5 days/week (12
exposures in 16 days) to 970 or 2090 ppm MIAK. CNS effects – slight lethargy
and lower aural response – were observed during the higher exposure. There were
also dose-dependent increases in absolute (not significant in males) and relative
liver weights, higher relative kidney weights (not significant in females at 2090
ppm), and, in males, histopathological changes (hyalin degeneration or hyalin
droplet formation) in epithelial cells in renal ducts. No indications of liver or
kidney damage were seen in clinical/chemical analysis, however (5). When rats
were exposed on the same schedule to 210, 1030 or 2080 ppm MIAK for 96 days
(69 exposures) a dose-dependent CNS effect was initially seen at the two higher
dose levels. Slight lethargy and lower aural response were observed later, but only
at the highest air concentration. Porphyrin-like discolorations around the eyes,
nose and mouth (regarded as indications of slight irritation), as well as significant,
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dose-dependent increases of absolute and relative liver weights, were also seen
at the two higher dose levels. Histopathological examinations revealed dose-
dependent liver changes, including minimal to moderate hypertrophy of hepato-
cytes and, in males, also minimal to mild necrosis. Effects on kidneys were seen
primarily in males. Indications of mild/moderate regeneration of epithelium in
renal tubules were seen at the two higher dose levels, though at 1030 ppm only in
males. Males in the highest dose group also showed indications of possible in-
crease in hyalin drop degeneration in the proximal convoluted tubules. Signifi-
cantly higher absolute and relative kidney weights were reported in males at the
two higher doses, and increased relative kidney weights in females at the highest
dose, although clinical-chemical examination revealed no indications of liver or
kidney damage. The NOEL in this study was 210 ppm (5).
An unpublished inhalation study reports that no exposure-related effects
were seen in rats after exposure to 400 ppm MIAK 6 hours/day, 5 days/week
(12 exposures). The same report describes effects observed when the animals
were given MIAK by gavage in doses of 1000, 2000 or 4000 mg/kg body weight,
5 days/week for 3 weeks. The highest dose resulted in CNS depression and all
the animals died within 1.5 hours. Effects seen at 2000 mg/kg included chronic
irritation of stomach lining, hypertrophy of hepatic cells and hyalin drop forma-
tion in kidneys. The only observed effect at 1000 mg/kg was slight irritation of the
stomach lining. It is also reported that oral administration of 2000 mg/kg b.w./day
to rats 5 days/week for 13 weeks resulted in somewhat elevated levels of hepatic
enzymes, increased absolute and relative liver and adrenal weights, higher relative
kidney weights and histopathological changes in the liver (degeneration,
hypertrophy, hyperplasia) and stomach lining (chronic irritation) (10).
Undiluted MIAK applied to the skin of rabbits caused no irritation within
24 hours: changes were ranked 1 on a 10-point scale. In the same study, MIAK
applied to eyes of rabbits was ranked 2 (8).
Mutagenicity, carcinogenicity, effects on reproduction
No data were found in the literature.
Dose-effect / dose-response relationships
Kane et al. (4), in a study of various irritating substances (not including MIAK),
found that the RD50 levels for mice often produce intolerable irritation in the eyes
and upper respiratory passages of humans, and that an air concentration equivalent
to 10% of the RD50 for mice usually causes some irritation in humans. A good
agreement has also been shown between the ACGIH threshold limit values (1991)
based on sensory irritation and air concentrations equivalent to 3% of the RD50,
i.e. the value midway between 1% and 10% of the RD50 on a logarithmic scale (7).
Dose-effect relationships documented in experimental animals exposed to MIAK
by inhalation are summarized in Table 1. The RD50 for mice is reported to be
about 1200 ppm, and a 27% reduction in respiratory rate is observed at about
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Table 1. Effects observed in experimental animals exposed to MIAK by inhalation.
Exposure Species Effects Ref.
2090 ppm,
6 hours/day,
5 days/week
(12 exposures)
Rat Slight lethargy, reduced aural response; somewhat
elevated liver and kidney weights; histopathological
changes in kidneys of males.
5
2080 ppm,
6 hours/day,
5 days/week
(69 exposures)
Rat Lethargy, reduced aural response; somewhat elevated
liver and kidney weights; histopathological changes in
liver and kidneys; slight irritation of eyes and respiratory
passages.
5
1232 ppm,
5 minutes
Mouse RD50 7
1222 ppm,
15 minutes
Mouse RD50 2
1030 ppm,
6 hours/day,
5 days/week
(69 exposures)
Rat Slight lethargy, initially reduced aural response;
somewhat elevated liver and kidney weights;
histopathological changes in liver, and in males also in
kidneys. Slight irritation of eyes and respiratory passages.
5
970 ppm,
6 hours/day,
5 days/week
(12 exposures)
Rat Somewhat elevated liver and kidney weights;
histopathological changes in kidneys of males.
5
416 ppm,
15 minutes
Mouse 27% reduction in respiratory rate. 2
210 ppm,
6 hours/day,
5 days/week
(69 exposures)
Rat No exposure-related effects. 5
400 ppm (2, 7). In a relatively large study with effects on liver, kidneys and CNS
as well as irritation, the NOEL was reported to be 210 ppm (5).
Conclusions
There are no data for human exposures on which to base a critical effect for
occupational exposure to MIAK. Limited data from animal experiments indicate
that the critical effect of short-term exposure is irritation of mucous membranes in
respiratory passages.
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Consensus Report for Toluene
February 6, 2002
This report is based primarily on a criteria document from the Nordic Expert
Group (162). The Criteria Group has previously published a consensus report for
toluene in 1981 (137).
Chemical and physical data. Uses.
CAS No.: 108-88-3
Synonyms: methyl benzene, phenyl methane, toluol,
methyl benzol, methacide
Molecular formula: C7H8
Structure:
Molecular weight: 92.13
Boiling point: 110.6 °C
Melting point: -95 °C
Density: 0.876 g/ml (20 °C)
Vapour pressure: 3.73 kPa (20 °C)
Saturation concentration: 142,000 mg/m3 (25 °C)
Conversion factors (25 °C): 1 ppm = 3.75 mg/m3
1 mg/m3 = 0.267 ppm
Toluene is a high production volume substance, and millions of tonnes are used
yearly. Toluene at room temperature is a clear colourless liquid with unpleasant
aromatic odour. The odour thresholds reported in various studies range from 1.5
to 262.5 mg/m3 (2, 43, 121). The reason for the variability in the reported odour
threshold is unknown. However, toluene can be detected in air in concentrations
at the lower end of the reported odour threshold range. In a volunteer study, in-
creased odour level was perceived at the lowest concentration tested, 37.5 mg/m3
(3). Toluene is only slightly soluble in water, approximately 6.5 mmol/l at 20 °C.
Toluene is soluble in acetone and carbon disulphide, and miscible with most
ethers, ketones, alcohols, esters, and aliphatic and aromatic hydrocarbons.
Toluene forms azeotropic mixtures with many of the solvents mentioned above.
Toluene is used as a solvent in a number of products such as bitumen, tar, paints,
lacquers, greases, and natural and synthetic resins. Workers in the chemical
industry and paint industry, and workers using products containing toluene (e.g.
CH3
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painters) may be occupationally exposed. The main exposure to toluene occurs by
inhalation of vapours and liquid aerosols and via dermal exposure to liquids.
Within production of toluene in the chemical industry, a reasonable worst case
short term exposure level is 100 mg/m3, while the typical full shift exposure level
is low, 3 mg/m3. For production of toluene-containing products, a reasonable
worst case short term exposure level is 200 mg/m3, while the typical full shift
exposure level is low, 4 mg/m3. Occupational use of toluene-containing products
can lead to high exposure levels. For use of toluene-containing adhesives and inks
the typical full shift exposure level is 75 mg/m3. These values derive from the EU
risk assessment of toluene (24).
Uptake, biotransformation, excretion
The major route of exposure to toluene is inhalation of vapour. Data from
experimental exposure of voluntary study subjects show that physical work
results in increased toluene uptake (16, 146). Using a 50 W work load, exposure
to 300 mg/m3 (80 ppm) toluene for 2 hours did not result in steady state of the
blood concentration of toluene in 12 study subjects. The toluene uptake was 2.4
times higher than the uptake at rest. During the work, lung ventilation increased
2.8 times. Concentrations of toluene in alveolar air and blood increased with
increasing work loads (0-150 W in periods of 30 minutes) (16). However, at
higher workloads the proportion of toluene taken up decreased (only 29% at 150
W compared with 52% at rest), indicating that the uptake is limited by the rate of
removal of toluene from the lungs via blood (77). The amount of toluene absorbed
increased with larger amounts of body fat (17). In nine male volunteers exposed to
200 mg/m3 (53 ppm) toluene for 2 hours during a workload of 50 W the total
uptake of toluene was 50% of that inhaled (78).
The steady state dermal penetration rate of neat toluene has been reported to be
14.5 nmol/cm2/min (80 µg/cm2/h) (145) using human skin in vitro. Similar values
of 8.5 and 12.5 nmol/cm2/min have been reported from animal experiments (140,
141). Applying the ECETOC criteria for skin notation (26), i.e. exposure of 2,000
cm2 of skin (approximately corresponding to the skin of the hands and forearms)
for 1 hour (equivalent to exposure of 250 cm2 skin or 70% of one hand for 8 h)
and using the above human data a dermally absorbed dose of 1.7 mmol toluene is
obtained. This corresponds to 16% of the amount absorbed during 8-h inhalatory
exposure at 50 ppm (10.8 mmol). The inhalation uptake was calculated assuming
exposure at the present Swedish OEL (50 ppm, 8-h TWA), 10 m3 inhaled air
during 8 hours and a pulmonary retention of 50%. In conclusion, dermal exposure
to liquid toluene may result in significant systemic exposure.
Experiments with volunteers indicate that upon whole body exposure to toluene
vapour, the dermal route contributes to about 1-2% of the systemic exposure (10,
103, 116).
Toluene appears to be well absorbed after oral exposure (162).
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Toluene is widely distributed in body tissues, including the placenta, and has
high affinity to adipose tissue. In humans the adipose tissue/blood partition
coefficient of toluene is 81-83 (123, 124).
Biotransformation of toluene occurs mainly by oxidation in the liver. About
20% of the absorbed toluene is eliminated unchanged in the expired air. Of the
remaining 80%, approximately 99% is oxidised via benzyl alcohol and benz-
aldehyde to benzoic acid. The remaining 1% is oxidised in the aromatic ring,
forming ortho-, meta- and para-cresol (157, 158). Benzoic acid is linked to
glycine forming hippuric acid, which is excreted in the urine.
Elimination curves for toluene in blood from exposed workers was found to
contain at least three exponential components with median half-lives of 9 minutes,
2 hours, and 90 hours, the latter value reflecting the decline of toluene in adipose
tissue (94). The half-life of toluene in human adipose tissue is about 3 days (17).
The time period during which accumulation occurs can be calculated by multi-
plying the half-life by 5, i.e. about 15 days, after which steady-state is reached.
The conclusion therefore is that although there is some accumulation of toluene it
is not an accumulative substance as such compared with, e.g. PCBs, which have a
half-life of several years.
Biological measures of exposure
Measurement of toluene in blood, urine and exhaled air provide reliable markers
of exposure to toluene. Measurement of toluene metabolites is also utilised for
monitoring toluene exposure in humans. Hippuric acid is formed in the body when
toluene is metabolised. High performance liquid chromatography (HPLC) with
ultraviolet detection is usually used for detection of hippuric acid in urine. Other
metabolites such as o-cresol, benzylmercapturic acid, or S-p-toluylmercapturic
acid may also be measured (143). A good correlation was found between toluene
exposure (air concentration multiplied by time) and concentration of hippuric acid
in post exposure urine. However, a background level of hippuric acid is present in
human urine, as a product of endogenous metabolism, and of metabolism of
substances present in food. In the Western part of the world, at exposure levels
below 100 ppm (375 mg/m3) hippuric acid in post exposure urine cannot be used
to separate an exposed person from an unexposed one because the difference
between the background level and the toluene-generated level is too small (74).
However, hippuric acid background levels in urine vary geographically. In some
countries (e.g. Taiwan and Croatia) a low urinary hippuric acid background level
is found. Thus, in these parts of the world it is possible to use this metabolite as a
biological marker for toluene exposure even at exposure levels lower than 100
ppm (19, 143, 147, 149).
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Toxic effects
Human data
Toluene has a degreasing effect on the skin. After repeated exposures, irritative
contact dermatitis may develop (11, 38, 153). A five-minute exposure to 1.5 ml
toluene on a skin surface area of 3.1 cm2 caused marked erythema and increased
blood flow measured by laser Doppler flowmetry (151). Studies in human volun-
teers exposed at rest show that deterioration in the air quality and increased odour
level is perceived around 10 ppm (37.5 mg/m3), while complaints of eye irritation
start at air concentrations around 100 ppm (375 mg/m3) (3, 27). Kidney damage
has been described as a consequence of high exposure levels in relation to work-
place accidents or abuse (114, 120, 143). Three older occupational studies did not
show a relation between toluene exposure and kidney damage (4, 34, 93). In a
recent longitudinal study of 92 photogravure printers and 74 referents, it was
concluded that toluene at 50 ppm (187.5 mg/m3) was not related to detectable
renal dysfunction assessed on the basis of various markers in blood and urine (131).
Acute neuropsychological effects of toluene has been investigated in a number
of studies in volunteers (3, 12, 13, 20, 27, 28, 53, 58, 112, 154). Headache, diz-
ziness, feeling of intoxication, irritation and sleepiness were reported in several of
the studies at toluene concentrations in the range of 75-150 ppm (281 mg/m3-
562.5 mg/m3). In one study, headache, eye irritation and increased number of
sleeping episodes occurred at 75 ppm (281 mg/m3) and above (27). At 150 ppm in
the same study, function in performance tests was impaired. As concentrations
below 75 ppm were not tested, this study does not provide a NOAEL (no observed
adverse effect level). Because of various limitations and uncertainties in design
and reporting, this study is not considered for further use.
Another study (3) reports that concentrations up to 40 ppm did not result in any
adverse effects. In this study, 100 ppm was a LOAEL (lowest observed adverse
effect level) for irritation of the eye and nose, headache, dizziness, feeling of
intoxication, and a feeling that performance tests were more strenuous. Six out
of 16 subjects did not report any irritation during the 100 ppm exposure, i.e. 10
subjects did experience irritation. The highest individual estimation was 64 on a
scale with a maximum value called strong irritation (=100). The irritation was felt
just after the exposure began and was constant throughout the exposure day.
Disruption of performance of complex tests and increased response time in
simple tests following exposure to 100 ppm for 6 hours (mostly at rest, 30 minutes
of moderate exercise during the exposure) was found in six healthy adults in a
two-period cross-over experiment where each subject served as his/her own
control (112). Effects of lower exposure levels were not studied.
The subjective experience and performance effects of a 6 h toluene-exposure
were studied in 43 printers and 43 subjects without previous history of chemical
exposure (12). Half of each group of subjects were exposed to air, half were
exposed to 100 ppm toluene at rest. Fatigue, irritation of eyes, nose and throat
was increased by toluene. Manual dexterity, colour discrimination and visual
perception were impaired.
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Humans exposed to very high levels of toluene as a result of toluene abuse or
industrial accidents may experience serious nervous system effects including fatal
CNS depression. Other effects include cerebellar, pyramidal and cognitive dys-
function such as tremor, ataxia and memory impairment. Brain atrophy attributed
to toluene exposure has been identified in heavy abusers (8, 32, 74, 75, 122, 143).
A number of cross-sectional studies, in which a toluene-exposed group of
workers have been compared with a matched control group, have been published.
Unfortunately, exposure data covering the subjects’ entire exposure history are
generally lacking in these studies, with only recent exposure being reasonably
well documented. As the effects observed in these cross-sectional studies may be
viewed as the accumulation of effects induced during the entire period of occupa-
tional exposure, which is often many years, it is necessary to have information
about the whole period in order to identify LOAELs and NOAELs for the effects.
It must be assumed that the exposure levels have changed during the years
because of changes in industrial operations and hygiene measures. These studies
have reported increased prevalence of subjective complaints (fatigue, recent
memory failure, concentration difficulty, mood lability, depressive feelings,
irritability, headache, dizziness, sleep disturbances, paresthesia, chest oppression,
sexual problems) (75, 161), neuropsychological impairments (6, 30, 35, 57),
electrophysiological changes (1, 148), and increased prevalence of neurasthenic
complaints, short-term memory complaints, and chronic toxic encephalopathy
(CTE) (72, 161) in the toluene-exposed group. In the latter study (161), exposure
levels in the two rotogravure plants concerned were estimated retrospectively
based on personal interviews, previous hygienic measurements and other written
reports concerning the working environment (Table 1). These estimates show that
irreversible effects may be induced at exposure during many years at concentra-
tions ranging from 40 to 1700 mg/m3. Even higher concentrations may have been
present in previous years.
Table 1. Estimated retrospective exposure levels for toluene at
two Swedish rotogravure plants, from Ørbæk and Nise (161).
Year      Retrospective exposure level (mg/m    3  ) 
Company A Company B
-1955 570a 1,710
1956-57 1,710 1,710
1958-68 1,710 1,710
1969 950 1,710
1970-72 950 950
1973-74 610 950
1975-76 610 380
1977 610 250
1978-79 300 250
1980- 43 157
aMixed Stoddard solvent exposure in letterpress printing
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Two cross-sectional studies in workers indicate that occupational exposure to
toluene increases the risk of developing occupational noise-related high-frequency
hearing loss (83, 84). In the first study (83) four groups of workers were studied:
unexposed (noise level <85 dB(A) and no toluene), noise exposed (noise level 88-
97 dB(A) and no toluene); noise plus toluene exposed (noise level 88-98 dB(A)
and toluene concentration 281-2250 mg/m3), and organic solvent mixture exposed
(noise level <85 dB(A) and exposure to four solvents). In the second study (84), a
group of workers exposed to varying levels of noise and a mixture of toluene,
ethyl acetate, and ethanol were studied. The toluene concentration was 0.14 to 919
mg/m3, and noise levels were in the range of 71-93 dB(A).
In two cross-sectional studies of workers occupationally exposed to toluene the
leukocyte count in peripheral blood has been measured (56, 142). A slight positive
correlation to toluene exposure was found in one of the studies (142), however,
the leukocyte count in the exposed group was within the range of normal values.
The other study did not show an association between increased number of leuko-
cytes and toluene exposure.
Animal data
Toluene was found slightly irritating to the skin in rabbits (41), and moderately to
severely irritating to the eyes, also in rabbits (42, 132). Toluene-induced skin
oedema following repeated topical administration has been measured in rabbits
and guinea pigs (150). The mean increase in guinea pig skin-fold thickness was
225% after 10 daily applications. The response in rabbits was similar. No
published data have been found regarding skin sensitisation by toluene.
Data from mice suggest that toluene can cause irritation to the respiratory tract
at high concentrations (25, 85, 92).
Toluene has low acute toxicity via inhalation and the oral route. In rats, in-
halatory LC50 values in the range of 20,000-50,000 mg/m3/6 h (7, 14) and oral
LD50 values of 5.5-7.5 g/kg have been reported (65, 128, 144, 156, 159). A dermal
LD50 of 12.4 g/kg has been determined in the rabbit (128). Via the intraperitoneal
route LD50 values were found to be approximately 2 g/kg for rats and mice (29,
55, 67, 76).
The effect of repeated inhalation has been examined in a number of studies in
rats and mice with exposure durations ranging from 15 weeks to 2 years (40, 51).
The most relevant studies for the prediction of effects of long-term exposure in
man are the 2-year studies. The major effect of toluene identified in rats exposed
for 2 years to 600 or 1200 ppm (2250 or 4500 mg/m3), was toxicity to the
olfactory and respiratory epithelium and was found in both males and females at
both exposure levels (51).
In other studies specifically examining the effects on the nervous system after
inhalation exposure in rats, various changes were found, including brain region
volume changes and neurochemical changes. The dose levels varied between 100
and 1500 ppm (375-5625 mg/m3) (49, 68, 70, 126, 127).
Auditory impairment of toluene-exposed rats has been demonstrated in a
number of studies as behavioural and electrophysiological changes at inhalatory
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exposure concentrations between 900 and 1400 ppm 14 h/day, 7 days/week, for 5-
14 weeks (109, 110, 111, 113). A LOAEL of 1000 ppm (14 h/day, 2 weeks) and a
NOAEL of 700 ppm (14 h/day, 16 weeks) was found. Studies on combined
exposure to toluene and noise strongly indicate that a synergistic toxic effect of
toluene and noise (1000 ppm toluene + 100 dB Leq (62); or 2000 ppm toluene +
92 dB SPL (73)) on auditory functions may exist (62). In rats exposed to toluene
plus hexane, each solvent in a concentration of 1000 ppm (3750 mg/m3 toluene), a
synergistic loss of auditory sensitivity was observed after 3 months (97). Toluene
exposure causes a progressive severe loss of hair cells in the cochlea (15, 60, 61,
73, 133).
Repeated oral dosing by gavage for 13 weeks caused neurone cell death in the
brain in rats that received 2500 or 1250 mg/kg/day (51).
Mutagenicity Carcinogenicity
Toluene is not mutagenic in Salmonella typhimurium (9, 21, 47, 52, 59, 88, 89,
130).
Toluene has not been found to induce DNA repair mediated toxicity to any of
several bacteria strain tested, gene conversion in the yeast Saccharomyces
cerevisiae or genotoxic effects in Drosophila melanogaster (59, 79, 80, 81, 87, 88,
117, 118, 155).
Toluene does not appear to induce biologically significant increases in
mutations, sister chromatid exchanges, micronuclei or DNA damage in vitro in
mammalian cells at non-cytotoxic doses (18, 39, 59, 115, 125, 129, 160).
Positive results have been obtained in three cytogenetic studies performed in
the former USSR in the 1970’s (54). It has, however, been implied that these
significant cytogenetic responses might be due to benzene contamination. In
more recent studies, toluene has not induced biologically significant increases in
micronuclei and chromosomal aberrations in the bone marrow of mice and rats or
DNA damage in peripheral blood cells, bone marrow, and liver of mice (37, 59,
81, 82, 105, 119). Toluene can be considered to be adequately tested and is
considered non-genotoxic in vivo.
Equivocal results were obtained in a multitude of studies with biological
monitoring of various genotoxic effects in peripheral blood lymphocytes from
workers exposed to toluene in the occupational environment (5, 33, 36, 44, 45, 64,
71, 86, 95, 102, 104, 107). In most cases confounding due to coexposure to ink,
other solvents and various genotoxic substances in the environment cannot be
excluded. Smoking, estimated to increase chromosomal aberrations by 10-20%
and sister chromatid exchange by 5-8% (96), was not considered in some older
studies (33, 36), and matching for this confounding factor was inadequate in other
studies (95, 102). A clear synergistic effect between toluene exposure and
smoking was demonstrated in one study, that is, the genotoxic effect of smoking
was enhanced by toluene (45).
Toluene was not carcinogenic in rats or mice exposed via inhalation for two
years (40, 51).
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Toluene has been used as vehicle control in a number of dermal cancer studies
in mice. No clear increase of skin tumours attributable to toluene was noted (54).
The carcinogenic potential of toluene has been evaluated by IARC (54). IARC
has evaluated toluene as not classifiable as to its carcinogenicity to humans (IARC
Group 3). In the evaluation, four case-control studies involving several anatomical
sites of cancer are mentioned. The results could not be evaluated with regard to
toluene itself, because the exposure was to mixtures of solvents and not to pure
toluene.
A cohort of 1020 rotogravure printers exposed to toluene and employed for a
minimum period of three months in eight plants during 1925-85 was studied.
Based on the measurements in the 1940’s and 1950’s the maximum toluene
concentration was about 450 ppm, but it was only about 30 ppm in the mid
1980’s. Exposure to benzene occurred until the beginning of the 1960’s.
Compared with the regional rates, total mortality was not increased during the
observation period 1952-86. There was no increase in mortality from non-
malignant diseases of the lungs, nervous system, or gastrointestinal and urinary
tracts. There was no overall excess of tumours in the years 1958-85. Among the
specific cancers, those of the respiratory tract increased significantly. However,
statistical significance was not attained, when only subjects with an exposure
period of at least five years and a latency period of at least 10 years were
considered, and no dose-response relationship could be established (135).
The mortality from various cancer forms in a cohort of 6830 male and 751
female workers in the German rotogravure industry has been investigated.
Mortality causes were based on death certificates. Because death certificates are
removed after five years in many German federal states, the true number of cause-
specific deaths was estimated mathematically based on the information on
available causes of death. The number of deaths was 466. Total mortality from
cancer (100 deaths observed, resulting in 122.7 estimated deaths) did not differ
substantially from the expected level of 127.7 deaths. A significantly higher
mortality due to bone and connective tissue tumours was identified, based on a
low number of cases (7 deaths observed, resulting in 7.9 estimated deaths versus
4.2 deaths expected). Also mortality due to lung+trachea+bronchus tumours (35
deaths observed, resulting in 43.6 estimated deaths versus 35.4 expected deaths),
and brain tumours and tumours of the nervous system was increased (6 deaths
observed, resulting in 9.1 estimated deaths versus 4.1 deaths expected), but not to
a level reaching statistical significance. Exposure information was very limited
and based on work area (152).
Reproductive effects
Human data
In two independent studies in rotogravure printers, effects on male hormones were
studied. The observed effects were rather small with most hormone levels being
within the reference limit. A correlation with present exposure concentrations was
found for the levels of some hormones. Although the effects cannot be regarded as
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directly adverse, the studies do give evidence that toluene might interfere with
endocrine mechanisms (134, 136).
The possible influence of toluene exposure on fertility was examined by
retrospective interviews in a German cross sectional study of 150 male and 90
female workers. The findings of the study indicate reduced female fecundity in
relation to low-level toluene exposure. The women worked exclusively in the
stacking and bookbinding process, and their estimated overall exposure (based
on measurements in previous years) was classified as low (<10 ppm) (106).
However, due to various limitations, clear conclusions cannot be drawn from this
study. Limitations in the study include potential for recall bias, i.e. persons with
undesirable outcome may have recall of exposure, which is different from those
who do not experience the outcome. More than one pregnancy per woman could
be included in the study, and such pregnancies cannot be regarded as independent
observations. Furthermore, the study suffered from an unvalidated low participa-
tion rate (39% for women). Reasons for non-participation were not investigated.
No evidence of menstrual disorders were found in female workers exposed to
toluene at a mean concentration of 88 ppm (330 mg/m3), range 50-150 ppm, in a
factory manufacturing audio speakers compared with an internal (exposed to 0-25
ppm toluene) and an external control group (90).
There have been several case reports of mothers giving birth to children with
so-called toluene embryopathy as a result of toluene sniffing during pregnancy.
Microcephaly, narrow bifrontal diameter, short palpebral fissures, deep-set eyes,
small midface, low-set prominent ears, micrognathia, spatulate fingertips, small
fingernails, hypotonia, and hyperreflexia were found in the children. In total about
45 cases have been described in the literature (101). These cases all very much
resemble the foetal alcohol syndrome, and there might be a common mechanism.
Among women working in laboratories, spontaneous abortions and congenital
malformations and birth weights of the children were examined in a retrospective
case-referent study (138). Significant associations with spontaneous abortions
were found for frequent exposure to toluene. No association with congenital
malformation was found, however, the number of persons in the malformation
study was too small for drawing final conclusions.
Rates of spontaneous abortions were determined using a reproductive
questionnaire in 55 women with 105 pregnancies exposed to toluene as the only
solvent (mean 88 ppm, range 50-150 ppm). 31 women (68 pregnancies) working
in the same factory in departments where little or no exposure to toluene occurred
(0-25 ppm) answered the same questionnaire. An external community control
group of 190 working class women who were receiving routine antenatal and
postnatal care in public maternal health clinics with 444 pregnancies were also
studied. The workers were exposed to fairly constant concentrations of toluene
during the workshift. Exposure to toluene was assessed by passive personal
sampling (31, 91). Only abortions from curettage after a diagnosis by a medical
practitioner were determined, and spontaneous and induced abortions were clearly
distinguished by probing questions as to the reasons for the curettage.
Spontaneous abortion was defined by its occurrence after 12 weeks and before 28
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weeks of pregnancy. Significantly higher rates for spontaneous abortions were
noted in the toluene exposed women compared with those in the internal and
external control groups (12.9% vs. 2.9-4.5%). The rate differences between
groups were not likely to be confounded by classical risk factors such as maternal
age, order of gravidity, smoking, or alcohol, which were taken into account both
in the study design and the analysis (91). A weakness in the study is that a few
women contributed with a large fraction of all spontaneous abortions (four women
contributed with 9 out of 13 spontaneous abortions in the high toluene exposure
group), but the employed (fixed effect) statistical models do not account for this
dependence between the observations. Use of a fixed effect model leads to an
underestimation of the uncertainty of the effect estimates in this context. A more
feasible approach would be to use a random effect logistic regression model.
However, the difference in spontaneous abortion rates between the high toluene
exposure group and the women receiving care at the maternal health clinic is
likely to stay significant with the random effect model.
Animal data
In a 15-week inhalation study no toluene-related effects on sperm morphology
and vaginal cytology in rats exposed to 100, 625, and 1250 ppm toluene 6.5 h/day,
5 d/week, were found. Significantly and dose-related decreased sperm count and
reduced epididymal weight was found in rats exposed via inhalation to a concen-
tration of 2000 ppm (7500 mg/m3) during 6 h/day for 90 days. The NOAEL was
600 ppm (2250 mg/m3) (99). Inhalation of high concentrations of toluene (4000-
6000 ppm) for 2 h/day for 5 weeks caused reduced sperm count and quality, and
reduced in vitro egg penetration ability. The exposure was also associated with
narcotic effect, lacrimation, ataxia and tremor and reductions in body weight gain
(98).
Lower foetal weight, lower birth weight and delayed postnatal development
have been reported in a number of studies (23, 46, 48, 50, 100, 139). The
LOAELs are in the range of 1000-2000 ppm (3750-7500 mg/m3). The NOAELs
are in the range of 400-750 ppm (1500-2812 mg/m3). A NOAEL for effects on
birth weight and postnatal development of 600 ppm (2250 mg/m3) can reasonably
be set.
Increased spontaneous activity and impairments of cognitive functions (learning
and memory) after exposure to toluene during brain development have been found
in two studies in rats. In one study, the dams were exposed at 0 or 1200 ppm
(4500 mg/m3) from gestational day 7 to postnatal day 18 (46). In the other study,
the dams were exposed to 0 or 1800 ppm (6750 mg/m3 on gestational day 7-20
(48, 100, 139). In both studies, the behaviour of the offspring was studied. The
LOAEL for the behavioural effects is 1200 ppm (4500 mg/m3) and a NOAEL
cannot be established since lower exposure levels were not investigated.
In mice, Courtney et al. (22) found some signs of foetotoxicity of toluene at
400 ppm (1500 mg/m3), the only dose level in this study. Jones and Balster (63)
exposed pregnant mice to air, 200, 400, or 2000 ppm toluene on gestational days
12-17 and found lower birth weight, decreased postnatal weight gain, and delayed
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reflex development in the absence of maternal toxicity at 2000 ppm toluene (7500
mg/m3). The NOAEL was 400 ppm (1500 mg/m3), but the daily exposure periods
were limited to 3 hours. Effects on behaviour in the absence of maternal or
general toxicity have been reported in mice after perinatal dosing via drinking
water with approximately 60 mg toluene/kg/day (69).
In rabbits equivocal effects were found in a study comprising two teratology
tests (66). In the first part of the study (n=14) slight delays in skeletal develop-
ment were registered at 500 ppm (1875 mg/m3). No effect was observed in the
second part of the study at the same exposure level (n=20).
Dose-effect / dose-response relationships
The effects of toluene have been extensively studied in humans and laboratory
animals. The key studies for evaluation of the important effects of toluene are
listed in Table 2 (human data) and Table 3 (animal data).
Liquid toluene is irritating to the skin and eyes in animals, while toluene
vapours in concentrations at and above 100 ppm causes complaints of the eye,
and nose and throat irritation in humans.
In the rat, a NOAEL for clinical and morphological signs of toxicity of 300 ppm
for repeated exposure via inhalation was identified in a 2-year study. In another 2-
year study higher exposure levels (600 ppm) resulted in nasal toxicity and in-
creased incidence of stomach ulcers. For the dermal route, no data on clinical and
morphological signs of toxicity have been found.
Toluene has been shown to affect the central nervous system and the inner ear.
In humans exposed at rest under experimental conditions to 100 ppm toluene
(375 mg/m3) headache, dizziness, feeling of intoxication, and irritation were
recorded to occur with significantly increased frequency. At 150 mg/m3 (40 ppm)
and below the effects have not been recorded to occur with increased frequency.
For these subjective symptoms a LOAEL of 375 mg/m3 (100 ppm) and a NOAEL
of 150 mg/m3 (40 ppm) can be established.
Experimental chamber inhalation of 375 mg/m3 (100 ppm) toluene for 6 hours
at rest has in two studies been shown to cause disruption of performance of
psychological performance tests, and in another study a feeling of tests being
more difficult and strenuous. In the latter study, a NOAEL of 40 ppm was found.
For acute neuropsychological effects, 100 ppm can be regarded as a LOAEL.
Chronic toxic encephalopathy (CTE) may be induced by toluene exposure
during many years at concentrations ranging from 40-1700 mg/m3. In the study
concerned, it is possible that even higher levels were present in earlier years.
Toluene is ototoxic in the rat and causes a progressive severe loss of hair cells
in the cochlea accompanied by hearing loss. The LOAEL in rats is around 1000
ppm (3750 mg/m3), and the NOAEL around 700 ppm (2625 mg/m3). In humans,
occupational exposure to toluene increases the risk of developing noise-related
hearing loss. The exposure concentrations in the studies where this has been
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Table 2. LOAELs (lowest observed adverse effect levels) and NOAELs (no observed
adverse effect levels) from human studies.
Concentration Exposure
duration
Effects Ref.
40-1700 mg/m3
10-450 ppm
possibly even higher
concentrations in
years preceding
exposure estimation
workplace,
> 4-43 years,
median 29 years
fatigue, recent short-term memory
problems, concentration difficulties,
mood lability, reduced psychometric
performance
(161)
375-1125 mg/m3
average exposure
levels 1978-1980:
140-600 ppm
1990: 75-365 ppm
Workplace Increased incidence of high-frequency
bilateral hearing loss (in the presence of
noise)
(51 noise+toluene-exposed, 50
unexposed, 50 noise-exposed, 39 organic
solvent mixture exposed)
(83)
375 mg/m3
100 ppm
6h LOAEL for impaired function
performance of psychological
performance tests
(12, 112)
375 mg/m3
100 ppm
6h LOAEL for irritation of eyes, nose and
throat
(12)
375 mg/m3
100 ppm
6h LOAEL for irritation of the eyes and
nose, headache, dizziness, and feeling of
intoxication
NOAEL for psychometric performance
(however tests felt more difficult and
strenuous)
(16 experimentally exposed subjects,
serving as their own control)
(3)
300 mg/m3
range 50-150 ppm
(mean 88 ppm)
workplace Increased rate of spontaneous abortion
(55 exposed, 31 internal controls, 190
external controls)
(91)
150 mg/m3
40 ppm
6h NOAEL for irritation of the eyes and
nose, headache, dizziness, and feeling of
intoxikation (16 experimentally exposed
subjects, serving as their own control)
(3)
37,5 mg/m3
10 ppm
6h LOAEL for deterioration in the perceived
air quality and increased odour level
(16 experimentally exposed subjects,
serving as their own control)
(3)
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Table 3. LOAELs (lowest observed adverse effect levels) and NOAELs (no observed
adverse effect levels) from animal studies.
Concentraion Exposure duration Species and effects Ref.
30 mg/m3
8000 ppm
4-6.5h Rat, lethal (LD50) (7, 14,
108, 128)
3750 mg/m3
1000 ppm
2 weeks Rat, LOAEL for auditory toxicity (111)
3750 mg/m3
1000 ppm
gestation
day 9-21
Rat, LOAEL for reduced birth weight and
retarded postnatal development
(139)
2625 mg/m3
700 ppm
16 weeks Rat, NOAEL for auditory toxicity (111)
2250 mg/m3
600 ppm
2 years Rat, LOAEL for nasal toxicity and
clinical and morphological signs of
toxicity (nasal toxicity and stomach
ulcers)
(51)
2250 mg/m3
600 ppm
gestation
day 9-21
Rat, NOAEL for reduced birth weight and
retarded postnatal development
(139)
1125 mg/m3
300 ppm
2 years Rat, NOAEL for clinical and
morphological signs of toxicity
(40)
shown were relatively high (in the first study 281-2250 mg/m3; in the second
study up to 919 mg/m3). The data cannot be used to identify a human NOAEL.
In toluene-exposed female workers a significantly higher rate of spontaneous
abortions was found. The mean toluene concentration was 88 ppm (333 mg/m3)
with a range of 50-150 ppm (188-563 mg/m3). At higher concentrations in animal
studies, toluene has been found to cause lower foetal and birth weight with a
LOAEL of around 1000 ppm (3800 mg/m3), and NOAEL around 600 ppm (2280
mg/m3). Long-lasting developmental neurotoxicity (impairment of learning
ability) has been demonstrated in offspring exposed prenatally or pre- and
postnatally with a LOAEL of 1200 ppm (4560 mg/m3). In male rats exposed to
2000 ppm (7600 mg/m3), reduced sperm count was found with a NOAEL of 600
ppm (2250 mg/m3).
Conclusions
The critical effects of toluene exposure are acute CNS effects, irritation and
spontaneous abortions. Headache, dizziness, feeling of intoxication, irritation
of the eyes, nose and throat and impaired function in neuropsychological tests
have been reported after experimental exposure of volunteers at rest for 6 h at
100 ppm (LOAEL). A NOAEL of 40 ppm (irritation) has been reported in healthy
volunteers. For spontaneous abortion (studied epidemiologically) the dose-
response relationship is not well known in terms of concentrations and duration
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of exposure. In one study an increased risk for spontaneous abortion was found
at concentrations varying between 50-150 ppm (average 88 ppm).
Other effects of concern are ototoxicity and chronic toxic encephalopathy.
Ototoxicity has been studied epidemiologically, and the dose-response relation is
not well known. However, ototoxicity has been thoroughly investigated in experi-
mental animals, and a LOAEL of 1000 ppm and a NOAEL of 700 ppm has been
identified. Chronic toxic encephalopathy has been studied epidemiologically, and
the dose-response relation is not well known. However, it is believed that an
individual must be exposed for many years before chronic toxic encephalopathy
occurs. In the study concerned, exposure concentrations ranged from 40-1700
mg/m3 (10-500 ppm), and it is possible that even higher levels were present in
earlier years.
Dermal exposure to liquid toluene may result in significant systemic exposure.
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Summary
Montelius J (ed). Scientific Basis for Swedish Occupational Standards. XXIII.
Arbete och Hälsa 2002:19, pp 1-63. National Institute for Working Life, Solna.
Critical review and evaluation of those scientific data which are relevant as a background
for discussion of Swedish occupational exposure limits. This volume consists of the
consensus reports given by the Criteria Group at the Swedish National Institute for
Working Life from July, 2001 through June, 2002.
Key Words: Isocyanic Acid (ICA), 4,4´-Methylenedianiline (MDA),
Methylisoamylketone, Methylisocyanate (MIC), Occupational exposure
limit (OEL), Risk assessment, Scientific basis, Toluene, Toxicology.
Sammanfattning
Montelius J (ed). Vetenskapligt underlag för hygieniska gränsvärden. XXIII. Arbete och
Hälsa 2002:19, s 1-63. Arbetslivsinstitutet, Solna.
Sammanställningar baserade på kritisk genomgång och värdering av de vetenskapliga
fakta, vilka är relevanta som underlag för fastställande av hygieniskt gränsvärde.
Volymen omfattar de underlag som avgivits från Kriteriegruppen för hygieniska
gränsvärden under perioden juli 2001 - juni 2002.
Nyckelord: Hygieniskt gränsvärde, Isocyansyra (ICA), 4,4´-Metylendianilin (MDA),
Metylisoamylketon, Metylisocyanat (MIC), Riskvärdering, Toluen,
Toxikologi, Vetenskapligt underlag.
En svensk version av dessa vetenskapliga underlag finns publicerad i Arbete och Hälsa
2002:18.
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Methyl-t-butyl ether November 26, 1987 1988:32 (IX)
revised September 30, 1998 1999:26 (XX)
Mixed solvents, neurotoxicity April 25, 1985 1985:32 (VI)
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Nickel April 21, 1982 1982:24 (III)
Nitroethane April 4, 1989 1989:32 (X)
Nitrogen oxides December 11, 1985 1986:35 (VII)
Nitroglycerin February 13, 1985 1985:32 (VI)
Nitroglycol February 13, 1985 1985:32 (VI)
Nitromethane January 6, 1989 1989:32 (X)
Nitropropane October 28, 1986 1987:39 (VIII)
2-Nitropropane March 29, 1995 1995:19 (XVI)
Nitroso compounds December 12, 1990 1992:6 (XII)
Nitrosomorpholine December 8, 1982 1983:36 (IV)
Nitrotoluene February 20, 1991 1992:6 (XII)
Nitrous oxide December 9, 1981 1982:24 (III)
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Organic acid anhydrides, some September 12, 1989 1991:8 (XI)
Oxalic acid February 24, 1988 1988:32 (IX)
Ozone April 28, 1987 1987:39 (VIII)
Paper dust February 7, 1990 1991:8 (XI)
Pentaerythritol November 16, 1994 1995:19 (XVI)
1,1,1,2,2-Pentafluoroethane February 24, 1999 1999:26 (XX)
Pentyl acetate June 14, 2000 2000:22 (XXI)
Peroxides, organic February 13, 1985 1985:32 (VI)
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Phosphorous chlorides September 30, 1998 1999:26 (XX)
Phosphorous oxides February 11, 1998 1998:25 (XIX)
Phthalates December 8, 1982 1983:36 (IV)
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revised October 31, 1989 1991:8 (XI)
Sulfur dioxide April 25, 1985 1985:32 (VI)
Sulfur fluorides March 28, 1990 1991:8 (XI)
Synthetic inorganic fibers March 4, 1981 1982:9 (II)
revised December 1, 1987 1988:32 (IX)
Synthetic organic and inorganic fibers May 30, 1990 1991:8 (XI)
Talc dust June 12, 1991 1992:6 (XII)
Terpenes, mono- February 17, 1987 1987:39 (VIII)
Tetrabromoethane May 30, 1990 1991:8 (XI)
Tetrachloroethane June 4, 1997 1997:25 (XVIII)
Tetrachloroethylene February 29, 1980 1981:21 (I)
1,1,1,2-Tetrafluoroethane March 29, 1995 1995:19 (XVI)
Tetrahydrofuran October 31, 1989 1991:8 (XI)
Tetranitromethane April 4, 1989 1989:32 (X)
Thioglycolic acid June 1, 1994 1994:30 (XV)
Thiourea December 1, 1987 1988:32 (IX)
revised June 2, 1999 1999:26 (XX)
Thiram October 31, 1989 1991:8 (XI)
Thiurams, some October 31, 1989 1991:8 (XI)
Titanium dioxide February 21, 1989 1989:32 (X)
Toluene February 29, 1980 1981:21 (I)
revised February 6 2002 2002:19 (XXIII)
Toluene-2,4-diamine November 1, 2000 2001:20 (XXII)
Toluene-2,6-diamine November 1, 2000 2001:20 (XXII)
Toluene-2,4-diisocyanate April 8, 1981 1982:9 (II)
revised May 30, 2001 2001:20 (XXII)
Toluene-2,6-diisocyanate April 8, 1981 1982:9 (II)
revised May 30, 2001 2001:20 (XXII)
1,1,1-Trifluoroethane February 24, 1999 1999:26 (XX)
Trichlorobenzene September 16, 1993 1993:37 (XIV)
1,1,1-Trichloroethane March 4, 1981 1982:9 (II)
Trichloroethylene December 14, 1979 1981:21 (I)
Trichlorofluoromethane June 2, 1982 1982:24 (III)
1,1,2-Trichloro-1,2,2-trifluoroethane June 2, 1982 1982:24 (III)
Triethanolamine August 25, 1982 1983:36 (IV)
Triethylamine December 5, 1984 1985:32 (VI)
Trimellitic anhydride September 12, 1989 1991:8 (XI)
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Trimethylolpropane November 16, 1994 1995:19 (XVI)
Trinitrotoluene April 17, 1991 1992:6 (XII)
Vanadium March 15, 1983 1983:36 (IV)
Vinyl acetate June 6, 1989 1989:32 (X)
Vinyl toluene December 12, 1990 1992:6 (XII)
White spirit December 16, 1986 1987:39 (VIII)
Wood dust June 17, 1981 1982:9 (II)
revised June 25, 2000 2000:22 (XXI)
Xylene February 29, 1980 1981:21 (I)
Zinc April 21, 1982 1982:24 (III)
Zinc chromate May 24, 2000 2000:22 (XXI)
Zinc dimethyl dithiocarbamate September 12, 1989 1991:8 (XI)
Ziram September 12, 1989 1991:8 (XI)
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